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Pheochromocytomas (PHEOs) derived from adrenal medulla and paragangliomas (PGLs) 
from sympathetic or parasympathetic paraganglia are rare neuroendocrine tumors. 
Incidence of PHEOs and PGLs is between 0.4–9.5 cases per one million people per year. In 
Finland about 10–15 PHEOs are diagnosed per year, but the incidence is rising. Sympathetic 
PGLs occur about one tenth as often as PHEOs, and parasympathetic PGLs constitute about 
20% of PGLs. PHEOs and sympathetic PGLs can secrete catecholamines, often in bouts, 
which makes the symptoms associated with these tumors very diverse, with high blood 
pressure being the leading symptom. 
 
During recent years, knowledge of the variable genetic background and pathogenesis of 
PGLs and PHEOs has increased, and about 30-40% of these tumors are known to be 
hereditary. However, prognosis and aggressiveness of an individual tumor cannot be 
unequivocally predicted histologically or with any biomarkers. The aim of this thesis was 
to find biomarkers in PHEOs and PGLs for diagnostic, prognostic, and predictive purposes. 
A special focus was the differences between metastatic and nonmetastatic tumors as well as 
between PGLs and PHEOs. 
 
The study cohort consisted of 153 consecutive PHEOs or PGLs operated from 147 patients 
during the years 1973–2009 at Helsinki University Hospital. Clinical information was 
collected from hospital records, and tissue microarray blocks were constructed for 
immunohistochemistry studies. Matrix-assisted laser desorption/ionization time of flight 
mass spectrometric profiling of 16 tissue samples was used to analyze N-glycan structures 
in eight metastasized and eight nonmetastasized tumors. In addition, five thyroid PGLs 
originating from the population-based European-American-Head-and-Neck-
Paraganglioma-Registry (European-American-HNPGL-Registry, Freiburg, Germany) were 
investigated. These PGL patients were tested for germ-line mutations of the genes, which 
have been associated with head and neck PGLs. 
 
Metastasized PHEOs and PGLs expressed significantly more intracytoplasmic human 
antigen R (HuR) protein immunohistochemically than nonmetastasized tumors. HuR’s 
target, cyclooxygenase-2 (COX-2), was increased in metastatic tumors too. The metastatic 
potential was also associated with higher proliferation and tumor necrosis. Five somatostatin 
receptors (SSTR1–5) showed individual and varying SSTR profiles in PHEOs and PGLs. 
The most abundant SSTRs were SSTR2 and SSTR3. Between metastatic PHEOs and PGLs 
the SSTR2 expression varied – all PGLs were strongly SSTR2 positive, while most PHEOs 






The N-glycan profile differed depending on the metastatic status of the tumor. Metastasized 
tumors expressed more fucosylation and complex fucosylation in their N-glycans. Based on 
different N-glycan profiles, metastatic and nonmetastatic tumors and also PGLs and PHEOs 
could be separated in principal component analysis. 
 
Extremely rare thyroid PGLs showed a strong association with succinate dehydrogenase 
(SDH) mutation. Of five patients with thyroid PGL, two had SDHB mutation and two SDHA 
mutation. In our Finnish cohort, 10% of PHEO and PGL patients had SDHB mutation and 
40% of these a metastatic disease. 
 
In conclusion, intracytoplasmic HuR is increased in most metastatic PHEOs and PGLs and 
can be used in the panel of prognostic markers in these tumors. HuR may have a role in 
malignant transformation. PHEOs and PGLs have individual variable SSTR1–5 profiles. 
Investigating the SSTR1–5 profile in PHEOs and PGLs can be beneficial in choosing 
somatostatin analog based imaging and therapy. Metastasized and nonmetastasized PHEOs 
and PGLs have differences in N-glycans. Those N-glycans, associated with aggressive 
disease, may possibly be used in the future as prognostic biomarkers. PHEOs and PGLs 




















Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare neuroendocrine tumors 
that are embryonically derived from the neural crest. Tumors that develop from the adrenal 
medulla are called pheochromocytomas. Histologically similar tumors that develop from 
sympathetic or parasympathetic paraganglia are called paragangliomas (Tischler 2008). 
Tumors originating from sympathetic cells, also called chromaffin cells, often secrete 
catecholamines leading to diverse symptoms related to catecholamine excess. 
Parasympathetic PGLs do not usually secrete catecholamines (Lenders et al. 2014, Davison 
et al. 2018). 
 
The name pheochromocytoma comes from the Greek phaios meaning “dark,” chroma 
meaning “color,” and cytom meaning “tumor” (Bausch et al. 2017, Sane 2009). The word 
“chromaffin” comes from chromium and affinity. Chromaffin cells can be visualized by 
staining with chromium salts, which oxidize catecholamines to form a brown color (Bausch 
et al. 2017). 
 
Diagnosis of PHEOs and PGLs is still a challenge both to clinicians and to pathologists, 
although knowledge has increased a lot during recent decades. New prognostic markers 
associated with metastatic potential are needed. The leading symptom of these tumors is 
high blood pressure, paroxysmal or sustained, but the symptoms can vary and therefore this 
tumor has been called a great mimicker (Thomas et al. 2015, Davison et al. 2018). 
 
All PHEOs and PGLs are regarded as having malignant potential and thus it is 
recommended to divide them into metastatic and nonmetastatic instead of malign and 
benign tumors (Tischler et al. 2017). About 10% of PHEOs and 15–40% of PGLs 
metastasize (Chrisoulidou et al. 2007, Harari and Inabnet 2011, Choi et al. 2015, Tischler 
et al. 2017). Metastatic potential of PHEOs and PGLs cannot be interpreted from 
morphology; thus no scoring system is completely validated today. However, some 
histological features are associated with metastatic potential, such as high proliferation and 
necrosis, and risk stratification of these tumors is recommended (Tischler et al. 2017). Major 
advancement has been achieved in genetics of these tumors and in demonstrating the impact 
of genetic background on pathogenesis, localization, clinical behavior, and prognosis. 
According to genetic background, tumors can be divided into three clusters with different 
pathogenesis (Crona et al. 2017). 
 
The treatment options for metastatic PHEOs and PGLs are limited, but with increasing 
knowledge of the individual pathogenesis and characteristics of these tumors, possibly new 







 Review of the literature 
 Adrenal gland and paraganglion system 
 Adrenal gland 
The triangular shaped adrenal glands are paired endocrine organs located near the superior 
poles of the kidneys in the retroperitoneal fat. The glands consist of a yellowish adrenal 
cortex, which secretes glucocorticoids, mineralocorticoids, and sex steroids, and a reddish-
brown medulla, which secretes catecholamines. The cortex and the medulla have different 
functions, morphology, and embryology (Ross and Pawlina 2006, Mescher 2013). During 
organogenesis, the intermediate mesoderm gives rise to the adrenal cortex and gonads 
within the urogenital ridge. At 4 weeks of human gestation an adrenogonadal primordium 
can be seen. By embryonic week 8, a distinct adrenal primordium separates from the 
gonadal primordium. Primitive sympathetic cells migrate from the neural crest to form the 
medulla, which is of neuroectodermal origin. The adrenal gland becomes encapsulated and 
by the ninth gestational week, a separate organ cranial to the kidney can be seen. The human 
fetal adrenal cortex has a thick, androgen-producing fetal zone, glucocorticoid-producing 
definitive zone, and a transitional zone between these two, which is thought to produce 
cortisol during the third trimester. The fetal zone forms 80–90% of the adrenal cortex during 
gestation. By birth the adrenal glands weigh 8–9 g each, about twice as much as those of an 
adult. Postnatally the fetal zone rapidly involutes (Kempna and Fluck 2008, Ross and Louw 
2015). 
 
The adrenal glands are surrounded by a connective tissue capsule from which trabeculae 
with blood vessels and nerves traverse into the adrenal parenchyma. The adrenals get arterial 
blood from superior, middle and inferior suprarenal arteries, which originate from phrenic 
and renal arteries and from the aorta. Vessels branch into capsular capillaries and further 
into fenestrated cortical sinusoidal capillaries supplying adrenocortical cells. Further blood 
drains into medullary capillary sinusoids. Medullary arterioles pass through cortical 
trabeculae bringing arterial blood to medullary cells. Thus the medulla has a dual blood 
supply (see Figure 1). Venules from cortical and medullary sinusoids drain into 
adrenomedullary collecting veins, which join to form the central adrenomedullary vein. On 
the right side, it further drains into the inferior vena cava, and on the left side it drains into 
the left renal vein. The adrenomedullary vein has a tunica media, longitudinally oriented 
smooth muscle cells, which can contract, decrease the volume of the gland, and enhane the 
hormone liberation from the medulla into the circulation. In addition, lymphatic vessels are 
present in the adrenal capsule as well as in the adrenal medulla. Lymphatic vessels probably 
participate in the delivery of high molecular weight products, like chromogranin A, from 





The medulla contains pale-staining, large chromaffin cells, connective tissue, blood as well 
as lymphatic vessels, and nerves. The chromaffin cells are organized as clusters and cords 
and contain the well-developed Golgi apparatus, rough endoplasmic reticulum, and the 
secretory vesicles, which are 100–300 nm in diameter. The chromaffin cells are divided into 
two separate types secreting either epinephrine or norepinephrine. Glucocorticoids released 
from the adrenal cortex induce the enzyme phenylethanolamine-N-methyltransferase, 
which further causes methylation of norepinephrine to epinephrine (Ross and Pawlina 2006, 
Mescher 2013, Davison et al. 2018). About 80% of the catecholamines secreted from the 
medulla are epinephrine. Chromogranins are large soluble proteins binding catecholamines 
with Ca2+ and adenosine triphosphate (ATP) in storage complexes that are released with 
catecholamines (Ross and Pawlina 2006, Mescher 2013). Chromogranins are used for 
diagnosing PHEOs and PGLs both biochemically and by immunohistochemistry (IHC). 
 
Chromaffin cells synapse with myelinated presynaptic sympathetic nerve fibers. Nerve 
impulses cause the release of acetylcholine in presynaptic axons which triggers exocytosis 
of secretory vesicles in chromaffin cells. The release of catecholamines prepares the body 
for maximum use of energy and maximum physical effort – the “fight or flight” situation. 
Axons of medullary ganglion cells reach the cortex and can regulate cortical hormone 
secretion as well (Ross and Pawlina 2006, Mescher 2013). 
 
The adult adrenal cortex is divided into three zones with different morphology and function 
(see Figure 1). The outermost zona glomerulosa secretes mineralocorticoids, with 
aldosterone being the most important. The renin-angiotensin system regulates secretion of 
mineralocorticoids. The zona fasciculata in the middle secretes mainly glucocorticoids and 
some weak androgens. The zona reticularis secretes weak androgens, mostly 
dehydroepiandrosterone (DHEA), its sulfated conjugate (DHEAS), and to some extent also 
glucocorticoids. Hormonal activity and growth of the inner zones are regulated through the 
hypothalamic-pituitary-adrenal axis. Corticotrophin-releasing hormone (CRH) from the 
hypothalamus regulates the secretion of the pituitary adrenocorticotropic hormone (ACTH) 




























Figure 1. Organization of the cells within the adrenal gland and their relationship to the 
blood vessels (from Ross and Pawlina 2016). 






 Paraganglion system 
Paraganglia are a neural crest derived groups of cells scattered throughout the body as small 
masses. The size varies from small microscopic masses up to visible 3 mm clusters. The 
largest paraganglia are the organ of Zuckerkandl, the aortic sympathetic paraganglia, and 
intercarotid paraganglia. The paraganglia are either sympathetic or parasympathetic. 
 
Sympathetic paraganglia are located in the adrenal medulla, in prevertebral and 
paravertebral sympathetic chains, and in the sympathetic nerves, like in the organ of 
Zuckerkandl, retroperitoneum, thorax, and pelvis (Figure 2A). Sympathetic PGLs can arise 
in these locations. 
 
Parasympathetic paraganglia are located mainly in the head and neck along the 
cervicothoracic branches of the glossopharyngeal nerve, along vagal and jugulotympanic 
nerves where parasympathetic PGL develop (Figure 2B). Some parasympathetic 
paraganglia like the carotid body paraganglia work as chemoreceptors. 
 
The paraganglia have neuroendocrine chief cells that contain neurosecretory vesicles. The 
chief cells are arranged into cell nests, which are surrounded by sustentacular cells and rich 




Figure 2A. Anatomical distribution of sympathoadrenal paraganglia. 
Figure 2B. Anatomical distribution of paraganglia in head and neck.  
(From Lack 2007, p. 283, Fig. 11.1; p. 323, Fig. 12.1.) 





 Pheochromocytomas and paragangliomas 
 
  Epidemiology and risk factors 
Incidence of PHEOs and PGLs ranges from 0.4 to 9.5 cases per one million people per year 
(Tischler et al. 2017). In Finland about 10–15 PHEOs are diagnosed yearly (Paronen et al. 
2013). Sympathetic PGL occur about one tenth as often as PHEOs. The incidence of PHEOs 
and sympathetic PGLs has been reported to have risen in recent decades (Berends et al. 
2018). The increased incidence is associated with a trend of smaller tumor size and higher 
patient age at diagnosis. The increase in incidence can at least partly be explained by an 
increased use of imaging studies and biochemical tests for PHEOs and PGLs (Berends et al. 
2018). 
 
PHEOs and sympathetic PGLs can occur at any age, but most patients are in their fourth or 
fifth decades of life. The tumors in children are more often PGLs and are usually hereditary. 
The incidence is equal in both sexes and the only known risk factor is hereditary background 
(Tischler et al. 2017). Of patients with hypertension, about 0.2–0.6% have a PHEO (Lenders 
et al. 2014, Gunawardane and Grossman 2017). 
 
The incidence of head and neck PGLs (HNPGLs) is estimated to be one case per 30,000–
100,000 people annually. They represent 20% of all PGLs and 0.6% of head and neck 
tumors (Tischler et al. 2017). The most common HNPGL is carotid body PGL (57%), the 
next common being jugular PGL (23%) (Erickson et al. 2001). Some hereditary syndrome 
is often behind an HNPGL, but also chronic hypoxic conditions such as a high-altitude 
environment and cyanotic heart disease are thought to predispose to HNPGLs (Tischler et 
al. 2017). 
 
Of all incidentally found adrenal tumors about 1.5–14% are PHEOs (Davison et al. 2018) 
and PHEOs are found as incidentalomas in approximately one fourth (Gunawardane and 














  Genetic basis, pathogenesis, and most important associated 
syndromes 
Hereditary background is found in about 30–40% of PHEOs and PGLs (Pillai et al. 2016, 
Crona et al. 2017, Tischler et al. 2017). At least 12 different genetic syndromes and 15 well-
characterized driver genes are associated with these tumors. From sporadic PHEOs and 
PGLs a somatic mutation in genes associated with hereditary PHEO and PGL syndromes 
can be found in 25–30% of cases. A known germ-line or somatic PHEO/PGL gene mutation 
can be found in about 60% of tumors (Favier et al. 2015, Pillai et al. 2016). 
 
Different mutations are associated with different pathogenesis. The Cancer Genome Atlas 
molecular taxonomy nowadays separates PGLs and PHEOs into three main clusters – 1) 
pseudohypoxic, 2) Wnt signaling, and 3) kinase signaling – according to the underlying 
mutation and different pathogenesis (Fishbein et al. 2017, Crona et al. 2017). The genotype–
phenotype correlations of hereditary PHEOs and PGLs are listed in Table 1. 
 
 Pseudohypoxic cluster of pheochromocytomas and paragangliomas 
Hypoxia exists when oxygen concentration is below 21%. In a pseudohypoxic state, cellular 
oxygen concentration is high enough, but oxygen cannot be processed further due to a 
distraction in the oxygen-sensing pathways (Jochmanova et al. 2014). Hypoxia and 
pseudohypoxia activate hypoxia-inducible factors (HIFs), which are transcription factors 
and are composed of an oxygen-sensitive α subunit and stable β subunit (Jochmanova et al. 
2014). Due to the accumulation of oncometabolites and the stabilization of HIFs under 
normal oxygen pressure, a pseudohypoxic cluster has a pathological hypoxic response. 
 
The pseudohypoxic group can be divided into at least two subgroups: 1) tricarboxylic acid 
(TCA)-cycle related and 2) VHL and EPAS1/HIF-2α related. Succinate dehydrogenase 
(SDHx), fumarate hydratase (FH), and malate dehydrogenase (MDH2) mutations belong to 
the TCA-cycle related cluster. Mutations in genes encoding these enzymes cause the 
accumulation of oncometabolites, such as succinate, fumarate and malate, which leads to 
stabilization of HIF and activation of its target genes. Mutation in VHL or EPAS1 genes 
leads to stabilization of HIF and activation of HIF target genes, for example those associated 
with angiogenesis, cell growth, hematopoiesis, and cell migration (Jochmanova et al. 2014, 
Crona et al. 2017). EPAS1 mutation activates different genes than VHL and SDHx and may 
in the future be a special subgroup (Crona et al. 2017). 
 
  Wnt signaling cluster of pheochromocytomas and paragangliomas 
Of sporadic PHEOs and PGLs, 5–10% are thought to arise via the Wnt signaling pathway. 
Mutations in this group have been found in cold shock domain containing E1 (CSDE1) or 
in gene fusion UBTF (upstream binding transcription factor)-MAML3 (mastermind-like 




pathways. These tumors may be more aggressive based on clinical evidence of frequent 
recurrence and metastasis (Fishbein et al. 2017, Crona et al. 2017). 
 
 
  Kinase signaling cluster of pheochromocytomas and paragangliomas 
The kinase signaling cluster includes mutations that cause abnormal activation of oncogenic 
kinase signaling pathways like RAS/RAF / extracellular signal-regulated kinase (ERK) and 
PI3-kinase / protein kinase B (AKT) / mammalian target of rapamycin (mTOR). The most 
common genes in this group are the RET (rearranged during transfection) proto-oncogene 
and neurofibromin 1 (NF1). Also, Myc-associated factor X (MAX), transmembrane protein 
127 (TMEM127), and kinesin family member 1B (KIF1B) are included in this group (Pillai 
et al. 2016). Activation of the RET oncogene (gain of function mutation) causes activation 
of the tyrosine kinase receptor, which leads to activation of the RAS/RAF/ERK and PI 3-
kinase/AKT/mTOR pathways. This increases cell proliferation, cell survival, and growth 
and can lead to development of a PGL or PHEO (Pillai et al. 2016). 
 
  Somatic mutations of pheochromocytomas and paragangliomas 
The rate of point mutations in PHEOs and PGLs is low, with a mean of 0.67 per megabase, 
the mutations becoming more frequent with age (Fishbein et al. 2017, Crona et al. 2017). 
The frequency of somatic point mutations in PHEOs and PGLs is between that of 
adrenocortical carcinomas (median 0.9 somatic mutations per Mb) and neuroblastomas 
(median 0.3 somatic mutations per Mb) (Lawrence et al. 2014, Zheng et al. 2016). The 
cancers exposed to external mutagens have about a 20-fold higher mutation rate (Lawrence 
et al. 2014). The burden of somatic mutations seems to be associated with aggressive disease 
(Fishbein et al. 2017). 
 
Somatic mutations in genes associated with inherited PGL and PHEO have been identified 
(Luchetti et al. 2015, Pillai et al. 2016, Crona et al. 2017). Chromosomal gains and losses, 
copy number, and epigenetic changes have been recognized in PHEOs and PGLs. Frequent 
chromosomal changes are losses of tumor suppressor genes in chromosomes 1p, 3q, gains 
in 9q, 17q, 19p13.3, 20q and losses in 11p, 11q, 6q, 17p, and 22 (Luchetti et al. 2015, 



















Table 1. Genotype–phenotype correlations of hereditary pheochromocytomas and 
paragangliomas. (modified from Tischler et al. 2017). Genes 1–11 are grouped in the 



















1 VHL VHL 9% +++ Rare 
Very 
rare 5% 
2 SDHD PGL 1 5–7% + ++ ++ <5% 
3 SDHSF2 PGL 2 <1% – – ++ Low 
4 SDHC PGL 3 1–2% Rare Rare ++ Low 
5 SDHB PGL 4 6–8% + +++ + 30–70% 
6 SDHA PGL 5 1–2% Rare + + Low 
7 EPAS1 PZS Very rare + +  29% 
8 EGLN2 Very rare + +  Unknown 
9 EGLN1 Very rare + +  Unknown 
10 FH 1% + + + >50% 
11 MDH2 Very rare  +  Unknown 
12 RET MEN2 5% +++ Rare 
Very 
rare <5% 
13 NF1 2% ++ Rare Very rare 12% 
14 TMEM127 1% ++ + + Low 
15 MAX 1% + + + 10% 
16 KIF1β Very rare    Unknown 
17 
 MEN1 Very rare +  + Unknown 
 










 Most important associated syndromes 
 
Familiar paraganglioma syndromes 1–5 
 
SDH is a mitochondrial enzyme containing four subunits: SDHA-D and two assembly 
factors SDHAF1 and SDHAF2 (Pillai et al. 2016). The SDH enzyme converts succinate to 
fumarate. In this process two electrons to the electron transport chain are generated. The 
SDHA and SDHB subunits are located in the mitochondrial matrix. The complex is 
anchored to the inner mitochondrial membrane by subunits SDHC and SDHD. The SDH 
mutations cause accumulation of succinate and production of reactive oxygen species. 
Increased succinate activates hypoxia-sensitive transcription factors and target genes. SDH-
deficient PGLs and PHEOs are of methylator phenotype with hypermethylated histones and 
promoter regions (Tischler et al. 2017). 
 
Mutations in genes encoding subunits of SDH complex II (SDHA-D and assembly factor 
SDHAF2) cause familiar paraganglioma-pheochromocytoma syndromes, PGL 1–5, which 
are autosomal dominant diseases with variable penetrance. These mutations cause the most 
common form of hereditary PGLs and PHEOs. Different subunit mutations have different 
genotype–phenotype correlations and different prognosis. Other important SDH mutation 
associated tumors are gastrointestinal stromal tumors, renal cell carcinomas, and pituitary 
adenomas (Table 2 Benn et al. 2015). 
 
The SDHB subunit mutation is the most common, estimated to occur in 6–8% of all PGLs 
and PHEOs, followed by mutation in the SDHD subunit, occurring in 5–6% of these tumors. 
About half of SDHB-mutation associated tumors are extra-adrenal, like abdominal or 
thoracic PGLs, and they are multifocal in about 10–25% of cases. SDHD-mutation 
associated tumors are mostly HNPGLs and are multifocal in about 60% of cases. SDHC-





















Table 2. Clinical features, associated tumors (penetrance) of PGL syndromes 1–5 (modified 








HNPGL Multifocal Metastatic RCC Other 




PGL 2 SDHAF 0 0 100% 0 0 0 – 
PGL 3 SDHC 0 Rare * 15–20% 0 Rare GIST 









* Lifetime prevalence not yet determined. 
GIST = gastrointestinal stromal tumor; HNPGL = head and neck paraganglioma; PA = 





Von Hippel–Lindau syndrome 
 
The autosomal dominant von Hippel–Lindau syndrome (VHL) is caused by a germ-line 
mutation in the VHL gene, which leads to development of different tumors. VHL is a tumor 
suppressor gene and about 20% are de novo mutations. The VHL protein is part of the 
ubiquitin ligase protein complex, which targets HIF1A/HIFα for ubiquitination and 
proteasomal degradation. When the VHL protein is inactive or in hypoxia, HIF1A and 
HIF2A stabilize and activate hypoxia-related genes, for example VEGF and cyclinD1. 
 
Hemangioblastomas in the retina and central nervous system occur in 80% of VHL patients. 
Other VHL-associated tumors are PHEOs and PGLs, neuroendocrine tumors, renal cell 
carcinomas, and pancreatic serous cystadenomas. In Finland the incidence of VHL 
syndrome is 1/53,000 (Orphanet Orpha number ORPHA892). VHL syndrome is divided 
into different genotype–phenotype correlations. No PHEOs exist in type 1. In type 2A-2B, 
PHEOs and other tumors are found; in type 2C only PHEOs develop. The PHEOs in VHL 
syndrome usually secrete norepinephrine and bilateral tumors are common (Martucci and 







Multiple endocrine neoplasia type 2 (MEN2) 
 
The RET protein, which is a receptor tyrosine kinase, regulates cellular proliferation and 
apoptosis. Activating (gain of function) germ-line mutations in the RET-proto-oncogene 
cause multiple endocrine neoplasia type 2 (MEN2), with an estimated incidence of 1/30,000 
(Tischler et al. 2017). 
 
MEN2 has three phenotypes: MEN2A, MEN2B, and familiar medullary thyroid carcinoma 
(MTC). MEN2A patients represent about 90% of MEN2 cases and have MTC in over 90% 
of cases, a 50% risk of developing PHEO, and a 15–30% risk of hyperparathyroidism. 
Patients with rare MEN2B have a 100% risk of developing MTC and a 50% risk of 
developing PHEO. They also have mucosal ganglioneuromas and marfanoid habitus. 
Patients with familiar MTC have only an increased risk of this neoplasm. PHEOs in MEN2 
usually produce epinephrine, and approximately half of them are bilateral. MEN2-






Neurofibrmatosis type 1 
 
Mutations in the NF1 gene cause autosomal dominant neurofibromatosis 1 (NF1) syndrome. 
The product of the NF gene is neurofibromin protein, which activates RAS GTPase. 
Neurofibromin functions as a tumor suppressor and its inactivation leads to increased RAS 
oncogene signaling (Tischler et al. 2017). 
 
NF1 patients have multiple neurofibromas, freckling of the axilla and/or groin, brain stem 
gliomas, café au lait spots, PHEOs, duodenal neuroendocrine tumors (NETs), and malignant 
peripheral nerve sheath tumors. Disease outcome and tumor burden varies (Tischler et al. 
2017). The prevalence of NF1 in Finland is about 1/4400 (Poyhonen et al. 2000). About half 
of the cases are de novo mutations. PHEO/PGL are relatively infrequent in NF1. 
Epinephrine secreting PHEOs are more common than PGLs (Martucci and Pacak 2014). 














 Somatostatin receptor expression in pheochromocytomas and 
paragangliomas 
Somatostatin is a tetradecapeptide that inhibits growth hormone release from the pituitary 
gland, has an antisecretory effect, and can inhibit proliferation both in normal tissues and in 
various endocrine tumors (Unger et al. 2008). Somatostatin has also some antiangiogenic 
effect (Korner 2016). 
 
Somatostatin receptors (SSTR) belong to the G-protein coupled membrane receptors and 
peptide receptors. In human neoplasias five different SSTR subtypes, SSTR1–5, can 
manifest in various combinations (Reubi 2003). Like in other NETs, they are all also 
expressed in PHEOs and PGLs (Reubi 2003, Elston et al. 2015, Kaemmerer et al. 2017). 
 
When somatostatin or its analogs bind to SSTR, the ligand–receptor complex internalizes 
and activates different intracellular signal transduction cascades (Korner 2016). The 
antisecretory effect is mediated via a reduction of cyclic adenosine monophosphate (cAMP) 
and calcium channel activity. Modulation of mitogen-activated protein kinase (MAPK) 
activity and the activation of phosphotyrosine phosphatases are involved in the 
antiproliferative effects of SSTRs. Phosphotyrosine phosphatase activation and a decrease 
in cAMP are brought about by all SSTRs. Different SSTR subtypes have a variable impact 
on MAPK activity. SSTR4 increases while SSTR3 and SSTR5 decrease MAPK activity. 
SSTR1 and SSTR2 can both increase and decrease MAPK activity (Vitale et al. 2018). 
Although receptor internalization is thought to be an important factor for tumor targeting 
with somatostatin analogs, interestingly even more potent tumor targeting has been achieved 
with somatostatin antagonists which internalize poorly or not at all (Korner 2016). 
 
In PHEOs and PGLs discordant results regarding SSTR1–5 expression have been published. 
Similarly, contradictory results of SSTR expression in SDHB-negative tumors have been 
reported (Mundschenk et al. 2003, Elston et al. 2015, Kaemmerer et al. 2017). In some 
works, the SSTR2 expression in PHEOs and PGLs has been the most abundant (Elston et 
al. 2015, Kaemmerer et al. 2017). In other works, SSTR3 has been the most dominant SSTR 
subtype (Mundschenk et al. 2003, Unger et al. 2008). Variable SSTR1, SSTR4, and SSTR5 
positivity has also been reported (Unger et al. 2008, Elston et al. 2015, Kaemmerer et al. 
2015). 
 
Octreotide, which has a high affinity for SSTR2 and low affinity for SSTR3 and SSTR5, is 
the most used somatostatin analog (Korner 2016). Somatostatin analogs have been used to 
control the hormonal activity of PHEOs and PGLs with variable results (Lamarre-Cliche et 
al. 2002, Duet et al. 2005, Elston et al. 2015). Radiolabeled somatostatin analogs can be 














  Clinical presentation 
 Location of pheochromocytomas and paragangliomas 
The paraganglion system includes the adrenal medulla, where PHEOs originate, and extra-
adrenal paraganglia, which can be sympathetic or parasympathetic. Paraganglion 
originating PGLs are situated in the region of autonomic nervous system ganglia and 
following nerves. Sympathetic PGLs may be found from the base of the skull to the pelvis 
along prevertebral and paravertebral sympathetic chains and nerve fibers. Parasympathetic 
PGLs usually arise in the head and neck along jugular and tympanic nerves and sometimes 
in the mediastinum along the vagal nerve (Tischler et al. 2017, Crona et al. 2017). The 
majority of these tumors are intra-adrenal PHEOs, approximately 85–90% (Gunawardane 
and Grossman 2017, Davison et al. 2018). Of extra-adrenal sympathetic PGLs, most are 
located below the diaphragm in the para-aortic area, near the adrenals, in the kidney hilus 
and organ of Zuckerkandl (Tischler et al. 2017). Intrathoracic PGLs constitute around 12% 
and urine bladder PGLs 10% of sympathetic PGLs. The most common location regarding 
HNPGLs is the carotid body (57%), followed by jugular (23%) and vagal PGLs (13%) 
(Tischler et al. 2017). Rare sites for PGLs are, for example, the thyroid (Castelblanco et al. 
2012), pancreas (Zhang et al. 2014), mesenterium (Mohd Slim et al. 2015), cauda equina 
(Sonneland et al. 1986), heart (Wang et al. 2015), and nasopharynx (Said-Al-Naief and Ojha 
2008) (Figure 3). 
 
The primary location of a tumor is important because PHEOs and PGLs arising in various 
locations have different genetic background, different behavior, and different prognosis 
(Tischler et al. 2017). Sometimes it can be impossible to determine the primary location of 
the tumor. In the neck region, it can be difficult to separate a cervical sympathetic PGL from 
a parasympathetic neck PGL. A large infiltrative tumor in the vicinity of the adrenal gland 
can be either an adrenal PHEO, which infiltrates the surrounding soft tissues, or a PGL 
































Orbita (Salinas-La Rosa 2015)  
Thyroid (Castelblanco et al. 2012)  
Aorticopulmonary (van Gelder et al. 1995) 
Heart (Wang.et al. 2015) 
Urinary bladder (Martucci et al. 2015) 
Prostate (Wang et al. 2013a) 
Mesentery (Mohd Slim et al. 2015) 
Cauda equina (Sonneland et al. 1986) 
Pancreas (Zhang et al. 2014) 
 
Nasopharynx (Said-Al-Naief and Ojha 2008)  





PHEOs and PGLs are called “the great mimickers” because the clinical presentation is very 
variable and sometimes it can take years from symptoms to diagnosis (Lenders et al. 2014, 
Thomas et al. 2015, Davison et al. 2018). The amount and quality of hormones secreted by 
the tumor have an impact on symptoms. Catecholamines act via α-, β-, and dopaminergic 
receptors. The receptors have different physiological actions and several subtypes 
(Gunawardane and Grossman 2017). The hormonal activity usually leads to diagnostic 
investigations because of hormonally-related symptoms, which are usually episodic, so-
called “spells,” and are associated with intermittent catecholamine release from the tumor. 
 
Factors that trigger hormone release can be, for example, general anesthesia, drugs, 
including contrast agents, metoclopramide, and β-adrenergic receptor blockers, trauma to 
the tumor, exercise, and postural change (Gunawardane and Grossman 2017, Davison et al. 
2018). Release of catecholamines can lead to life-threatening crises (Davison et al. 2018) 
with serious consequences: intracranial hemorrhage, severe arrhythmias, heart failure, and 
pulmonary edema. Therefore, a nonmetastatic PHEO or hormonally active PGL can also be 
fatal (Jimenez et al. 2017). 
 
Some PHEOs and PGLs may be asymptomatic. Nonfunctional tumors usually cause 
symptoms because of the growing tumor size, including pain and nerve paralysis (Tischler 
et al. 2017, Crona et al. 2017). 
 
Periodic or sustained hypertension is the leading symptom of hormonally active tumors and 
can be difficult to treat. The classic triad – episodes of palpitation, headache, and profuse 
sweating – occur in 25–40% of patients (Tischler et al. 2017, Davison et al. 2018). The 
presence of hypertension with this classic triad should lead thoughts to PHEO or 
catecholamine-producing PGL. 
 
Other symptoms of PHEOs and PGLs are pallor, anxiety, panic attacks, and abdominal pain 
(Tischler et al. 2017). The most common symptoms are listed in Table 3. High 
norepinephrine production can lead to constipation, which occurs in 6% of patients (Thosani 
et al. 2015). PHEOs can also cause paraneoplastic syndromes like Cushing syndrome caused 
by the overproduction of ACTH (Nijhoff et al. 2009) and polycythemia due to production 
of erythropoietin (Pacak et al. 2013). Increased sensitivity of erythropoietin receptors can 
occur in PHEOs and PGLs with HIF2A or EGLN1/2 mutations (Yang et al. 2015). Also, 
vasoactive intestinal peptide secretion with watery diarrhea, hypokalemia, and achlorhydria 

















Table 3. Frequency of signs and symptoms (%) of pheochromocytomas. (modified from 
Lenders et al. 2005). 
 
 
Signs and symptoms Frequency (%) 
Sustained hypertension 50–60 
Paroxysmal hypertension 30 







Weight loss 20–40 
Tiredness 25–40 









  Diagnosis 
Biochemical measurements of catecholamines and their metabolites as well as imaging 
studies are the basis of diagnosis after clinical suspicion has arisen. Because of the high 
prevalence of genetic background, genetic consulting and testing is recommended for every 
PHEO and PGL patient (Lenders et al. 2014). 
 
 
  Biochemical evaluation of pheochromocytomas and paragangliomas 
Indications for biochemical tests are hypertension, especially treatment-resistent 
hypertension, episodic symptoms referring to catecholamine production, incidental adrenal 
mass, and known hereditary predisposition to PGL or PHEO (Davison et al. 2018). 
 
Catecholamine production can be demonstrated biochemically from plasma or urine, the 




metanephrines from urine reflect O-methylation of catecholamines in tumor cells. They are 
recommended for the initial testing (Lenders et al. 2014). Measuring free metanephrines 
from plasma together with the dopamine metabolite 3-methoxytyramine gives slightly 
higher sensitivity (99%) than urinary metanephrines (95%) (Lenders et al. 2014, Lenders 
and Eisenhofer 2017). Different methods can be used to measure catecholamines and 
metanephrines, like high-performance liquid chromatography and liquid chromatography / 
mass spectrometry. Catecholamine values four times above the normal range point strongly 
toward chromaffin cell originating tumors (Martucci and Pacak 2014). 
 
Most PHEOs produce mainly epinephrine with a varying amount of norepinephrine. Most 
PGLs secrete predominantly or exclusively norepinephrine (Tischler 2008, Lenders and 
Eisenhofer 2017). The catecholamine profile can be a clue to genetic syndromes. The 
dopamine metabolite 3-methoxytyramine either alone or combined with other 
catecholamine metabolites can point toward SDHB, SDHC, or SDHD mutation. Tumors 
associated with MEN2 or NF1 usually produce epinephrine, with high levels of 
metanephrine in plasma or urine. In VHL syndrome, isolated norepinephrine and 
normetaepinephrine production can be detected (Eisenhofer et al. 2011, Eisenhofer and 
Peitzsch 2014, Tischler et al. 2017). 
 
Chromogranin A, a polypeptide secreted by chromaffin cells, is elevated in plasma in 91% 
of PHEO/PGL patients. It is also elevated in other neuroendocrine tumors and even in 
neuroendocrine hyperplasias. It is thus not specific to PHEOs and PGLs, but it can be 
valuable in the follow-up. By combining catecholamine measurement with 
chromogranin A, a very high diagnostic sensitivity is possible (Grossrubatscher et al. 2006, 
Martucci and Pacak 2014). 
 
 Imaging studies 
An important part of diagnosis is imaging. Anatomical location or functional status, giving 
information of possible treatment options, can be estimated. Examples of imaging methods 
used are 123I-metaiodobenzylguanidine (MIBG) scintigraphy or somatostatin analog 





CT is a sensitive first line imaging modality when a tumor is suspected (Lenders et al. 2014). 
PHEOs and PGLs have variable appearance at CT. They usually have a rich capillary 
network, can be solid or cystic, heterogenous or more homogenous, and with or without 
calcifications (Gunawardane and Grossman 2017). Most PHEOs have Hounsfield units 
(HUs) over 10 (Blake et al. 2004, Davison et al. 2018). In contrast washout evaluation, these 
tumors have variable patterns, the majority of PHEOs having a delayed washout (Blake et 







Magnetic resonance imaging 
 
Magnetic resonance imaging (MRI) is useful in the localization of tumors, especially with 
HNPGLs and rare intracardial PGLs. MRI is also informative in metastatic disease (Lenders 
et al. 2014, Lenders and Eisenhofer 2017). Most tumors have a high signal intensity at T2-
weighted imaging and low signal intensity at T1-weighted imaging (Gunawardane and 
Grossman 2017). MRI is the preferred imaging method due to the lack of radiation exposure 
especially in children and pregnant women, and in the follow-up of SDHx mutation carriers 





The radiopharmaceutical agent MIBG is an analog of noradrenaline and accumulates mostly 
in catecholamine-producing cells and in electron-dense catecholamine storing granules. 
MIBG imaging can be used for confirmation of diagnosis of adrenal lesions, to search for 
metastasis of PHEOs and PGLs, and for estimation of suitability of MIBG therapy. Tissues 
innervated by the sympathetic system, for example the heart and salivary glands, take up 
MIBG. 
 
123I-labeled MIBG can be visualized with single-photon emission computed tomography 
(SPECT) or SPECT combined with CT (SPECT-CT). 123I-labeled MIBG has a specificity 
of 70–100% for PHEOs and 84–100% for PGLs, and a sensitivity of 85–88% for PHEOs 
and 56–75% for PGLs (Gunawardane and Grossman 2017, Davison et al. 2018). Because 
of the low sensitivity (less than 50%) for metastatic PGLs and especially for SDHB-related 
PGLs, other imaging modalities are recommended for these tumors, except if iodine-131 
(131I) MIBG based therapy is planned (Lenders et al. 2014). Some drugs can interfere with 
MIBG scanning, for example tricyclic antidepressants, labetalol, and sympathomimetics. 
Also, strong physiological uptake or small tumor size can interfere with image interpretation 
(Gunawardane and Grossman 2017, Davison et al. 2018). 
 
 
Somatostatin analog positron emission tomography computed tomography 
 
Because the majority of PHEOs and PGLs express somatostatin receptors, labeled 
somatostatin analogs can be used for imaging PHEOs and PGLs, visualized with PET 
combined with CT (PET-CT) (Davison et al. 2018). The octapeptide octreotide or its 
modifications are used as ligands, which are fused to chelators and labeled with various 
radiometals (Ambrosini et al. 2011). Instead of the traditional octreotide scintigraphy, more 
sensitive DOTANOC/DOTATATE ligands are increasingly used (Davison et al. 2018). 
DOTANOC has a high affinity for SSTR2, 3, and 5 (Ambrosini et al. 2011). 68Ga-
DOTANOC PET-CT has good accuracy for both SDHx-related and sporadic metastatic 
PHEOs and PGLs. It is also useful for the imaging of HNPGLs (Lenders and Eisenhofer 
2017, Davison et al. 2018). Because same ligands used in imaging can be used also in 
peptide receptor radionuclide therapy (PRRT), SSTR imaging is important when estimating 






FDG positron emission tomography computed tomography  
 
PET with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG), which is an analog of 
glucose, visualizes cancer cells based on their increased glucose uptake and glycolysis and 
indicates metabolic abnormalities before morphological alterations occur. 18F-FDG PET/CT 
combines simultaneous PET and CT data and gives an exact anatomical localization of the 
18F-FDG PET positive lesions (Almuhaideb et al. 2011). 18F-FDG PET is sensitive in 
metastatic PGLs and PHEOs, especially in SDHB-related disease (Timmers et al. 2007, 





  Preoperative and surgical treatment 
 
Surgery is the only curative treatment for PHEOs and PGLs. With good preoperative 
medical preparation, modern anesthesia, and surgical techniques, perioperative mortality 
rates are low at less than 1% (Lenders and Eisenhofer 2017). However, operation of a 
catecholamine-producing tumor is a high-risk procedure and a multidisciplinary team 
including different specialist experienced surgeons, endocrinologists, and anesthesiologists 




Adequate preoperative medication is necessary to make the operation safe. The purpose of 
this is to prevent dangerous complications due to massive bouts of catecholamine being 
released from the tumor. These preparations are recommended even for normotensive, 
asymptomatic patients (Lenders et al. 2014, Gunawardane and Grossman 2017, Lenders and 
Eisenhofer 2017). PHEO/PGL patients should always go through a proper cardiovascular 
evaluation to rule out possible left ventricular, even subclinical, failure (Lenders and 
Eisenhofer 2017). To achieve effective α blockage, most centers use a noncompetitive α-
adrenoceptor blocker from one to two weeks before operation. Calcium channel blockers 
can also be used in addition. After proper α-adrenoceptor blockage, β-adrenoceptor 
blockage can be used to control tachycardia and tachyarrhythmias. Before and during 
operation, sufficient liquid balance should be guaranteed (Lenders et al. 2014, Gunawardane 




In patients with a PHEO, the standard surgical technique in operation is laparoscopic, 
minimally invasive removal of the adrenal gland by either a posterior retroperitoneal or 
transperitoneal approach (Barczynski et al. 2014, Gunawardane and Grossman 2017). For 




tumor resection and to avoid tumor rupture leading to local recurrences (Lenders et al. 
2014). Operation techniques for PGLs depend on the location and tumor size (Lenders and 
Eisenhofer 2017). Partial adrenalectomy could be the preferred option in patients with 
hereditary tumor to avoid lifelong steroid replacement therapy (Lenders et al. 2014, 
Castinetti et al. 2016). 
 
 
 Radiation therapy 
 
 
Besides radionuclide therapies – 131I-MIBG and PRRT – direct external irradiation can be 
given as palliative treatment, for example for bone metastases. Radio-frequency ablation 




131I-MIBG has been used as palliative treatment since the 1980s for metastatic PHEOs. 
Tumors that are positive in imaging with 123I-MIBG can be treated with 131I-MIBG. Labeled 
MIBG is transported into tumor cells. Emitted β radiation causes radiation-induced cell 
death (Castellani et al. 2010, Jimenez et al. 2017, Roman-Gonzalez and Jimenez 2017, 
Davison et al. 2018). 131I-MIBG can be given as multiple relatively low doses or as a limited 
number of high doses. Soft tissue metastases respond better than bone metastases. Adverse 
effects, which are usually dose dependent, are seen in 47–54% of patients receiving MIBG 
therapy. These adverse effects include anorexia, nausea, vomiting, hypothyroidism, ovarian 
failure, leukopenia, and thrombocytopenia (Castellani et al. 2010, Jimenez et al. 2017, 
Davison et al. 2018). 
 
Ultratrace iobenguane I-131, a new radiopharmaceutical agent which contains no unlabeled 
MIBG and has high specificity, is a promising improvement in the MIBG treatment options 




Peptide receptor radionuclide therapy 
 
Peptide analogs having affinity for SSTRs can be coupled with a suitable radioisotope, for 
example lutetium-177 (177Lu) or yttrium-90 (90Y), to give targeted peptide receptor 
radionucleotide therapy (PRRT) to patients with SSTR-positive tumors at imaging (Korner 
2016). Only a few reports on PRRT treatment for metastatic PHEOs or PGLs have been 
published, but results are promising. Nastos et al. (2017) studied 22 patients who had 
progressive or metastatic PGL or PHEO. Of 30 treatments two were with 177Lu 
DOTATATE, 12 with 90Y-DOTATATE, and 16 with 131I-MIBG. PRRT-treated patients had 
significantly increased progression-free survival and response to treatment compared with 




only patients with PGLs, overall survival, progression-free survival, event-free survival, and 
response to treatment were significantly better in the PRRT-treated group than in the 131I-
MIBG treated group (Nastos et al. 2017). 
 
Radionuclide treatment is less toxic than conventional cytotoxic agents. It reduces hormonal 
secretion by the tumor (Gunawardane and Grossman 2017). However, severe adverse 
reactions have been described in association with PRRT therapy for PGLs and PHEOs, 









Chemotherapy is given as palliative treatment for metastatic PHEOs and PGLs. The most 
common chemotherapy combination, used since 1985, is cyclophosphamide, vincristine, 
and dacarbazine (Roman-Gonzalez and Jimenez 2017). Chemotherapy may relieve 
symptoms, slow down tumor growth, and even shrink the tumor (Martucci and Pacak 2014). 
Niemeijer et al. (2014) reported partial response in tumor volume in about 37% of patients 
and partial response in catecholamine secretion in about 40% of patients, but the authors 
could not exclude overestimation of response, because some initiations of treatments were 
poorly described in the studies included in this review (Niemeijer et al. 2014). 
 
About 50% of patients with newly diagnosed metastatic PHEO or PGL, who were treatment 
naive, had minimal or no progression of disease one year after diagnosis. They had no 
symptoms of tumor burden, and catecholamine excess could easily be controlled with 
medication (Hescot et al. 2013). Thus, patients most likely to benefit from chemotherapy 
are those with rapidly progressing tumor burden, those with bone metastases, and those with 




New targeted medicines and future medicines 
 
Large studies on the use of somatostatin analogs in PHEOs and PGLs are lacking. Lamarre-
Cliche et al. carried out a prospective study including 10 patients with metastatic or recurrent 
PHEO treated with slow-release octreotide three times in an interval of one month. They 
found no significant difference in symptoms, blood pressure, metanephrine excretion, 
plasma catecholamine, or chromogranin A concentrations measured one month after the 
third injection (Lamarre-Cliche et al. 2002). Duet et al. gave three doses of long-acting 
somatostatin analog to eight patients with 18 HNPGLs every 28 days and measured tumor 
size one month after the third injection. The average shrinkage in HNPGLs was 4.0±10.0%. 




acting somatostatin analogs are being developed with affinity to more than one SSTR 
subtype. 
 
Many multi-tyrosine kinase inhibitors have been studied in the treatment of metastatic PGLs 
and PHEOs, for example sunitinib, axitinib, pazopanib, and cabozantinib, which all inhibit 
angiogenesis (Jimenez et al. 2017, Roman-Gonzalez and Jimenez 2017). Some metastatic 
PHEOs and PGLs use a hypoxia–pseudohypoxia environment to grow and survive. This 
environment may keep the immune system from recognizing neoplastic cells and have a 
tumor-promoting effect by immunosuppression. The immune checkpoint receptor, 
programmed cell death protein 1 (PD-1), prevents immune attack on tissues. Many cancers 
are capable of producing proteins that activate PD-1 receptors. Pembrolizumab is an 
antibody that blocks the PD-1 receptor in the lymphocytes and helps the immune system to 
attack neoplastic cells. Studies where metastatic PGL and PHEO patients are treated with 
pembrolizumab are currently ongoing (Roman-Gonzalez and Jimenez 2017). 
Temozolomide, an oral alternative to dacarbazine, was a promising treatment alternative for 
patients with SDHB mutation associated metastatic PGLs and PHEOs in a study by Hadoux 
et al. (2014) which included 15 patients, but another paper could not confirm this result 
(Ayala-Ramirez et al. 2012). SDHB-mutated tumors have O-methylguanine-DNA 
methyltransferase (MGMT) promoter hypermethylation. Silencing of MGMT expression 





  Gross appearance and histopathology 
 
 
Tumor morphology can often predict outcome. However, in PHEOs and PGLs 
histopathology is a poor predictor of prognosis. Many different scoring systems have been 
proposed for PHEOs and PGLs, but none of them is completely validated or accepted. 
 
Macroscopy 
PHEOs and PGLs are usually 2–6 cm in diameter, but some tumors may be over 10 cm. 
Tumor color can be gray-pink, violet, or tan when fresh tissue is seen and often yellow after 
formalin fixation (Figure 4). Hemorrhage, degenerative changes, and cystic change are 
common (Tischler et al. 2017). 
 
Histopathology 
Wide variation of cytological features and architecture can be seen in PHEOs and PGLs. 
The tumors are composed of polygonal chief cells, which can be reminiscent of normal 
chromaffin cells of the adrenal medulla. Tumor cells may have granular, pale, or basophilic 
cytoplasm. Nuclear and cellular pleomorphism are often seen, and the cell size varies a lot 
(Figure 4). Spindle tumor cells and intracytoplasmic hyaline globules can be sometimes 
found. PHEOs and sympathetic PGLs have a similar morphology. Parasympathetic PGLs 





Growth pattern can appear as the classic cell nests “Zellballen”. Also, diffuse or trabecular 
growth or even large confluent nests can be found. A second cell population is called 
sustentacular cells and can be demonstrated at the periphery of the chief cell nests or 
scattered between chief cells. These cells can be visualized by immunohistochemical 
staining for S-100 protein and glial fibrillary acidic protein (GFAP). The proportion of 
sustentacular cells varies and a lack of these cells has been associated with more aggressive 
tumors (Tischler 2008, Feng et al. 2009). 
 
Fibrous bands and a rich vascular network are found between tumor cells. Tumors have 
often hemorrhage and hemosiderin deposits. Also, composite tumors having components of 
neurogenic tumors such as ganglioneuroma, ganglioneuroblastoma, neuroblastoma, or 
peripheral nerve sheath tumor, and PHEOs exist (Tischler et al. 2017). 
 
Although no histological scoring system can unequivocally predict the metastatic potential 
of a tumor, some histological features are associated more often with metastatic disease, and 
thus a risk stratification for tumors is recommended. Features associated with metastatic 
PHEOs and PGLs include five broader categories: 1) invasive growth (periadrenal and 
surrounding soft tissue, vascular or capsular invasion), 2) cytological features (spindle cells, 
cellular monotony, small cells, high cell density, extreme pleomorphism), 3) necrosis, 4) 
proliferation (increased Ki-67 index, increased amount of mitoses or atypical mitoses), and 
5) architectural variation (diffuse growth, enlarged confluent cell nests) (Tischler et al. 
2017). 
 
The two most acknowledged scoring systems are Thompson’s Pheochromocytoma of the 
Adrenal Gland Scaled Score (PASS) (Thompson 2002) and Grading of Adrenal 
Pheochromocytoma and Paraganglioma (GAPP) (Kimura et al. 2014a, b). The PASS score 
has only histological features and is valid only for PHEOs. Tumors with a PASS score ≥4 
can behave more aggressively. The GAPP score includes histological parameters, an 
immunohistochemical Ki-67 index, as well as hormonal activity of the tumor. According to 
the score, tumors are divided into three risk categories: well-differentiated (0–2 points), 
moderately differentiated (3–6 points), and poorly differentiated (7–10 points), with 
different survival and risk of metastases. 
 
Salmenkivi et al. scored histologically 105 PHEOs and PGLs. All metastatic tumors had at 
least one histologically suspicious feature: >5 mitoses/10 high power field (HPF), necrosis, 
and capsular or vascular invasion. Tumors with histologically suspicious features but 
without metastases were called borderline tumors (Salmenkivi et al. 2003a). These different 
scoring systems include common features. They are presented in Table 4, where similar 






Table 4. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) (Thompson 2002) 
on the left, grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP) score 
(Kimura et al. 2014a) on the right, and Salmenkivi score below (Salmenkivi et al. 2003a). 
For scoring systems, common parameters are highlighted in the same color. 
 
PASS score   GAPP score  
     
Histomorphological parameter Score  Parameters Points scored 
Nuclear hyperchromasia 1  Histological pattern  
Profound nuclear pleomorphism 1  Zellballen 0 
Capsular invasion 1  Large and irregular cell nests 1 
Vascular invasion 1  Pseudorosette (even focal) 1 
Extension into periadrenal adipose 
tissue 2 
 Cellularity  
Atypical mitotic figures 2  Low (<150 cells/U)* 0 
Greater than 3 mitotic figures / 10HPF  2  Moderate (150–250 cells/U) 1 
Tumor cell spindling 2  High (more than 250 cells/U) 2 
Cellular monotony 2  Comedo necrosis  
High cellularity 2  Absence 0 
Central or confluent tumor necrosis 2  Presence 2 
Large nests or diffuse growth (>10% of 
tumor volume) 2 
 Vascular or capsular invasion  
Total maximum score 20  Absence 0 
   Presence 1 
HPF = high power field.   Ki-67 labeling index  
   <1 0 
   1–3 1 
   >3 2 
   Catecholamine type  
   Epinephrine type (E or E+NE) 0 
   Norepinephrine type (NE or 
NE+DA) 
1 
   Nonfunctioning type 0 
   Total maximum score 10 
     
     
   * U: area of grid of 10×10 mm, on eyepiece 









Histologically suspicious features 
 
    
Necrosis     
Vascular invasion     
Capsular invasion     








 Immunohistochemistry and differential diagnosis 
 
IHC is an important tool in confirming the diagnosis of PHEO or PGL and in differential 
diagnosis (Table 5). PHEOs and most PGLs are strongly positive at chromogranin A 
staining, but some HNPGLs can have weak or even negative chromogranin A staining. 
PHEOs and PGLs express also other neuroendocrine markers such as synaptophysin, CD56, 
and neuron-specific enolase (NSE). Cytokeratins are negative, with the exception of some 
parasympathetic PGLs like filum terminale PGL that have been reported to express 
cytokeratin (DeLellis et al. 2004). Sustentacular cells express S-100 and/or GFAP (Tischler 
et al. 2017). PHEOs and PGLs have variable SSTR1–5 positivity (Elston et al. 2015). 
 
SDHB IHC is a good method for screening possible genetic background of PGLs and 
PHEOs. All SDHx mutations result in the loss of SDHB protein, which can be shown 
immunohistochemically as SDHB-negative staining (Figure 4). In addition, a SDHA 























PHEO or PGL + + − − − − − − 
Adrenal cortical 
neoplasia − +/− +/− + +/− − − − 
Neuroendocrine 
tumor + + + − − − +/− − 
Renal cell carcinoma − − + − − − − − 
Urothelial carcinoma − − + − − − −/+ − 
Hepatocellular 
carcinoma − − + − − − + − 
Adenocarcinoma − − + − − − +/− − 
Melanoma − − − + − − − − 
Lymphoma − − − − − − − + 
Medullary thyroid 
carcinoma + + + − − + +/− − 
 
CEA = carcinoembryonic antigen. 






























Figure 4 A) A nonmetastatic PHEO in adrenal medulla. B) Variable nuclear size and basophilic 
cytoplasm in a metastatic PHEO. C) Tumor necrosis in a metastatic PHEO. D) Mitoses in a 
metastatic PHEO E) SDHB-deficient tumor cells in IHC. Endothelial cells stain positively as an 







 Metastatic pheochromocytomas and paragangliomas and factors 
associated with metastatic potential 
All PHEOs and PGLs are considered to have a varying degree of metastatic potential. It is 
more accurate to call these tumors nonmetastatic and metastatic rather than benign and 
malignant (Tischler et al. 2017). About 15–40% of PGLs and 10% of PHEOs metastasize 
(Harari and Inabnet 2011, Choi et al. 2015, Tischler et al. 2017). The diagnosis of metastatic 
disease should be done with caution as metastases should be found at a site where 
paraganglionic tissue is not normally present to exclude the possibility of multiple primary 
tumors. In particular, patients carrying a susceptibility gene mutation can have multiple 
primary tumors. About 50% of patients with metastatic PHEOs and PGLs develop 
metastases metachronously. It can take years or even decades after initial diagnosis for 
metastases to appear (Ayala-Ramirez et al. 2011, Ayala-Ramirez et al. 2013). The most 
common locations for metastases are the lymph nodes (80%), skeleton (72%), lungs (50%), 
and liver (50%) (Jimenez et al. 2017). 
 
Up to 34–60% of patients with metastatic disease are alive after 5 years from discovery of 
metastases (Tischler et al. 2017). Thus, progression of metastatic disease is variable and 
difficult to predict. Some patients can have indolent disease with a good quality of life for 
several years, while others have aggressive fast spreading disease with poor response to 
treatment (Jimenez et al. 2017). Liver and lung metastases are associated with shorter 
survival than bone metastases (Ayala-Ramirez et al. 2013). In addition, SDHB mutation 
associated metastatic disease has a worse prognosis (Blank et al. 2010, Martucci and Pacak 
2014, Tischler et al. 2017). 
 
In a study by Zelinka et al. (2011), age at diagnosis was an independent risk factor regardless 
of genetic background. The mean age for patients with metastatic disease was 41.4 years 
and that of nonmetastatic disease 50.2 years. Dhir et al. (2017) studied 157 PHEOs/PGLs 
(44 malignant, 113 benign). Patients with metastatic disease were younger – median 
42 years versus 50 years. In multivariable analysis, younger age was associated with 
malignancy (Dhir et al. 2017). 
 
Tumor location is a prognostic factor. PGLs metastasize more often than PHEOs. PGLs 
with highest metastatic rate are located under the diaphragm in the para-aortic area, in the 
organ of Zuckerkandl, and in the mediastinum (Ayala-Ramirez et al. 2011). Of vagal PGLs, 
approximately 16% metastasize, whereas metastases in all HNPGLs are found only in about 
4–6% of cases (Tischler et al. 2017). 
 
The size of the primary tumor predicts the outcome of both PHEOs and PGLs. In a study 
by Eisenhofer et al., primary metastatic tumors were 3.6-fold larger in volume than 
nonmetastatic PHEOs and PGLs. The mean tumor size for metastatic tumors was 7.2 cm 
and for nonmetastatic tumors 4.7 cm (Eisenhofer et al. 2012). Ayala-Ramirez et al. (2011) 
studied the size of PHEOs and PGLs of 290 patients, 89 having a metastatic disease and 201 
a nonmetastatic disease. The median tumor size was 8.2 cm for metastatic tumors and 
4.9 cm for nonmetastatic tumors (P<0.0001). However, 16% of metastatic tumors were 
smaller than 5 cm, the majority of these being PGLs (78.6%). Also, in a study by de Wailly 
et al., metastatic PHEOs were significantly larger than nonmetastatic PHEOs (de Wailly et 
al. 2012). The median survival time for patients with tumors 5 cm or larger was shorter than 





In multivariate analysis, location was a more powerful predictor of metastases than size. For 
the TNM staging of PHEOs and PGLs, a cutoff value of 5 cm was chosen between classes 






Table 6. TNM staging of tumors of the adrenal medulla and extra-adrenal paraganglia 







Hormonal activity of the tumor can give a clue to the metastatic potential of a PHEO or 
PGL. Catecholamine synthesis in poorly differentiated tumors can be incomplete, leading 
to deficient production of noradrenaline. Therefore, metastatic tumors can produce high 
levels of dopamine and its metabolites. In particular, elevated levels of 3-methoxytyramine 
may be associated with metastatic disease (Eisenhofer et al. 2012, Gunawardane and 
Grossman 2017, Lenders and Eisenhofer 2017). Also, very high serum chromogranin A 
levels have been associated more often with metastatic disease (Gunawardane and 
Grossman 2017). Metastatic tumors also produce more often noradrenaline (Zelinka et al. 
2011). 
 
Tumors with different genetic background have different metastatic potential. SDHB germ-
line mutation is one of the strongest factors predicting metastatic disease (Baysal and Maher 
2015). SDHB mutation leads to activation of HIFs, which have over 100 target genes 




death, cancer stem cell maintenance, and proliferation. However, activation of HIF-
dependent genes does not explain the metastatic potential alone because other SDHx-
mutated tumors are less aggressive. One explanation could be that the hypermethylation 
phenotype, associated with SDHB-mutated PHEOs and PGLs, would abnormally activate 
the epithelial-mesenchymal transition (Letouze et al. 2013, Loriot et al. 2012, Roman-
Gonzalez and Jimenez 2017). 
 
Germ-line mutations in the FH gene (Castro-Vega et al. 2014) and EPAS1/HIF2A gene 
(Tischler et al. 2017) are associated with an aggressive disease. Wnt signaling tumors, which 
are sporadic tumors, and tumors having UBTF-MAML3 gene fusion or CSDE1 mutation are 
also thought to be aggressive. The burden of somatic mutations seems to be associated with 
aggressive PHEOs and PGLs (Fishbein et al. 2017). Somatic NF1 and ATRX mutations have 
been associated with metastatic potential (Burnichon et al. 2012, Fishbein and Nathanson 
2017). VHL- and RET-associated PHEOs metastasize in less than 5% of cases 
(Gunawardane and Grossman 2017). 
 
The proliferation index of Ki-67 IHC is frequently used to estimate the aggressiveness of 
many different neoplasias. High Ki-67 index has been reported in metastatic PHEOs and 
PGLs as well. De Wailly et al. studied 53 PHEOs with seven metastatic cases. Metastatic 
PHEOs had significantly higher Ki-67 values, and high Ki-67 also correlated with tumor 
necrosis. All metastatic tumors had Ki-67 >4%, but one nonmetastatic PHEO had a Ki-67 
of 11% (de Wailly et al. 2012). In a study of 43 tumors by August et al., 85% of tumors with 
MIB1/Ki-67 over 5% metastasized (August et al. 2004). Also in other studies, a relationship 
between high Ki-67 index and aggressive behavior of PHEOs and PGLs has been shown 
(Tavangar et al. 2010b). However, metastatic tumors with low Ki-67 index exist and some 
nonmetastatic tumors show relatively high proliferation, so Ki-67 has only a limited value 












Other markers associated with metastatic potential of pheochromocytomas and 
paragangliomas 
Because histology gives us scant information of the prognosis of PHEOs and PGLs, a lot of 
studies have tried to find biomarkers associated with the metastatic potential of these tumors 






Table 7. Biomarkers associated with metastatic potential of pheochromocytomas (PHEOs) 
and paragangliomas (PGLs). 
 
 






Upregulated Boltze et al. 2003 
Heat shock protein 90 Upregulated Boltze et al. 2003, Xu 




Increased Xu et al. 2013 
Vascular endothelial 
growth factor 
Increased Salmenkivi et al. 
2003b 
Tenascin Increased Salmenkivi et al. 
2001a 
Cyclooxygenase-2 Increased Cadden et al. 2007, 
Saffar et al. 2011, 
Salmenkivi et al. 
2001b 
Inhibin α Decreased Salmenkivi et al. 
2001c 
C-erbB-2 Increased Tavangar et al. 2010  
Secretogranin II 
derived peptide 
Decreased Yon et al. 2003 
SNAIL Increased Hayry et al. 2009 
CD-44-S Decreased August et al. 2004 
nm23 Decreased Saffar et al. 2011 








In nearly all proteins, during or after protein synthesis, covalent changes occur that modify 
protein conformation, stability, localization, and function (Xin and Radivojac 2012, 
Grammatikakis et al. 2017). In posttranslational modification, small chemical groups like 
methyl, phosphate, acetyl, lipids, carbohydrates, or other amino acids can be added or 
removed (Grammatikakis et al. 2017). One of the most complex posttranslational 




posttranslational modifications can participate in tumorigenesis and malignant 
transformation (Grammatikakis et al. 2017). 
 
Regulatory processes after mRNA transcription, posttranslational control, are an important 
part of gene expression control in eukaryotes and influence final protein levels. This control 
of mRNA metabolism enables cells to adapt quickly to changing environmental conditions 
(Garcia-Maurino et al. 2017). RNA-binding proteins (RBPs) are important factors in this 
regulation and posttranslational modifications occur also in RBPs. Human antigen R (HuR), 
also known as ELAVL1 (embryonic lethal abnormal vision-like 1), is an RBP which 
regulates many target mRNAs. Posttranslational modifications of HuR have an impact on 
its ability to bind target RNA and on its subcellular localization (Grammatikakis et al. 2017). 
 
 
 Human antigen R and its target cyclooxygenase-2 
 
HuR is a product of the human ELAV1 gene and a member of the ELAV / human antigen 
family, which has four members. HuR is expressed ubiquitously. HuB/Hel-N1, HuC, and 
HuD occur mainly in neuronal tissues (Wang et al. 2013b, Grammatikakis et al. 2017). HuR 
is an ARE-RBP that often binds transcripts in the 3´-untranslated region of eukaryotic 
mRNA at RNA stretches enriched in adenylate or uridylate (ARE = adenylate/uridylate rich 
element) (Garcia-Maurino et al. 2017; Grammatikakis et al. 2017). AREs are present in 5–
8% of human genes (Garcia-Maurino et al. 2017). Many cancer-related genes, proto-
oncogenes, tumor suppressors, antiapoptotic factors, growth factors, and cyclin-dependent 
kinase inhibitors are targets of HuR (Wang et al. 2013b) (Figure 5). HuR affects mainly the 
stability and transcription of mRNA but also targets pre-RNA splicing and nuclear export 
of mRNA (Grammatikakis et al. 2017). Final RNA expression will be affected by RBP 
competition for the same transcript and dynamic ARE-RBPs/mRNA interactions (Garcia-
Maurino et al. 2017). 
 
HuR has been associated with pathological conditions such as cancer, chronic inflammation, 
and cardiovascular and neurological disease. HuR is also involved in physiological 
processes like response to stress and immunoagents, adipogenesis, and muscle 
differentiation. The amount of HuR regulates its function, but mainly posttranslational 
mechanisms such as phosphorylation, methylation, and ubiquitination affect HuR function 
(Grammatikakis et al. 2017). 
 
HuR consists of three RNA recognition motifs (RRMs). The first two domains (RRM1 and 
RRM2) bind RNA, and RRM3 is important for stability of the RNA-protein complex. 
Between RRM2 and RRM3 is a “hinge region” which contains the HuR nuclear shuttling 
domain, important for moving HuR from the nucleus to the cytoplasm and back. In 
unstimulated cells, HuR is mainly nuclear. In response to various stimuli, including 
mitogens and stress signals, HuR will be transported to the cytoplasm (Grammatikakis et al. 
2017). Increased cytoplasmic HuR expression has been found in many malignant tumors, 
for example in glioblastomas and medulloblastomas (Nabors et al. 2001), in Merkel cell 








Figure 5. Diverse functions of human antigen R (HuR) in cancer development and 
progression through the regulation of stability or translation of target mRNAs that encode 
multiple cancer-related proteins. COX-2 = cyclooxygenase-2; EGF = epidermal growth 
factor; ER = estrogen receptor; GATA3 = trans-acting T-cell-specific transcription factor; 
GM-CSF = granulocyte-macrophage colony-stimulating factor; IL-6 = interleukin-6; IL-13 
= interleukin-13; iNOS = inducible NO synthase; MMP-9 = matrix metalloproteinase-9; 
prot α = prothymosin α; TGF-β = transforming growth factor-β; TLR4 = toll-like receptor-
4; TNF-α = tumor necrosis factor-α; TSP-1 = thrombospondin 1; uPA = urokinase-type 
plasminogen activator; uPAR = urokinase-type plasminogen activator receptor; VEGF = 










Cyclooxygenase-2 (COX-2), also known as prostaglandin-endoperoxide synthase 2, is a 
target of HuR. Cytoplasmic HuR expression is associated with high COX-2 expression in 
colorectal adenocarcinomas (Denkert et al. 2006), mucinous-type ovarian carcinomas 




(Cha et al. 2011), and non-small-cell lung carcinomas (Giaginis et al. 2015). COX-1 and 
COX-2 catalyze the initial step of prostanoid synthesis, i.e., prostaglandins and 
thromboxanes. Prostaglandins regulate different pathophysiological processes such as 
inflammatory reaction, renal hemodynamics, intestinal cytoprotection, hemostasis, and 
thrombosis. COX-1 is expressed constitutionally in most tissues and participates in 
prostaglandin production in normal physiological processes. COX-2 is inducible by various 
mitogenic and inflammatory stimuli. It is connected to the formation of carcinogens, 
angiogenesis, tumor promotion, inhibition of apoptosis, and metastatic process (Ghosh et 
al. 2010). Increased COX-2 levels have been reported in metastatic PHEOs and PGLs 





Human cells are covered with glycans, which are carbohydrate units of glycoproteins, 
glycolipids, and proteoglycans. Glycan biosynthesis is a complex posttranslational event. 
About 1% of the human genome participates in it (Lowe and Marth 2003). The glycan 
structures have great variability, which leads to differences in biological and chemical 
properties. Glycosylation occurs mainly in the Golgi apparatus and endoplasmic reticulum 
but also in the nucleus and cytoplasm (Marth and Grewal 2008). Glycans can be divided 
into six principal families: 1) asparagine-linked (N-linked) glycans occurring mainly on 
glycoproteins, 2) serine- or threonine-linked (O-linked) glycans occurring mainly on 
membrane-bound mucins and glycoproteins, 3) glycosaminoglycans appearing as free 
polysaccharides or as part of proteoglycans, 4) glycosphingolipids, which consist of 
oligosaccharides binding to ceramide, 5) various nuclear and cytoplasmic proteins having 
O-linked N-acetylglucosamine, and 6) glycosylphosphatidylinositol-linked proteins 
(proteins which have a glycan linked to phosphatidylinositol) (Fuster and Esko 2005). 
 
Glycans participate in important functions of intercellular signaling, cell adhesion, and cell 
motility (Marth and Grewal 2008). Alterations of these functions can lead to malignant 
transformation and can also be demonstrated as changes in cells’ glycan profiles (Hakomori 
1989, An et al. 2009). Some structural changes in glycans are associated with tumor 
aggressiveness, and on the other hand some structural alterations in glycans may serve as 
biomarkers in malignant tumors (Hakomori 1989, Okuyama et al. 2006, Arnold et al. 2008). 
 
Changes in N-glycan structures have been identified in many cancers, for example lung 
(Satomaa et al. 2009a, Arnold et al. 2011), colorectal (Balog et al. 2012, Kaprio et al. 2015), 
and breast cancers (Abd Hamid et al. 2008). These cancer-associated N-glycan structures 
can participate in tumor growth (Girnita et al. 2000, Komatsu et al. 2001), angiogenesis (Pili 










 Aims of the study 
 
The major single aim of this thesis was to find biomarkers in PHEOs and PGLs for 
diagnostic, prognostic, and predictive purposes. A special focus has been on finding 




1. To study HuR protein expression and its prognostic relevance in PHEOs and PGLs. 
 
2. To evaluate SSTR1–5 subtype profiles of PHEOs and PGLs, and possible associations of 
the SDHB status with the SSTR subtypes in these tumors. 
 
3. To assess differences in N-glycosylation between nonmetastatic and metastatic PHEOs 
and PGLs. 
 
4. To determine characteristics of thyroid PGLs, their frequency, histological and 










 Material and methods 
 Patient cohorts, tissue samples, and histopathological 
parameters 
Studies I and II included consecutive patients with PHEO or PGL treated during years 
1973–2009 at Helsinki University Hospital. Tissue samples from primary tumors were 
collected from the archives of the Department of Pathology, Helsinki University Hospital. 
The accuracy of diagnosis was verified. Clinical data were collected from hospital records 
and survival data from the Finnish Population Register Centre. The cause of death was 
obtained from Statistics Finland. The mean follow-up time was 14.2 years (median 
13.9 years). Follow-up range for metastatic tumors was 0–41.1 years. One patient died 
during operation. For nonmetastatic tumors the follow-up range was 0.9–28.1 years. The 
patient with short follow-up died for reasons not related to the tumor. 
 
In Study I the tumors were divided into three categories (Groups A–C) according to 
histopathological parameters. Group A consisted of nonmetastatic tumors without 
worrisome histology (n=70). Group B (n=68) included nonmetastatic tumors with histology 
including at least one of the following: tumor necrosis (sharply demarcated necrosis, 
possible signs of inflammation, and shadows of neoplastic cells), capsular (through the 
tumor capsule) and vascular invasion (in capsule or outside the tumor), and MIB1 ≥5%. 
Group C included 15 metastasized tumors of which 13 had a worrisome histology. From a 
patient with a metastatic disease, two PGLs were included in Study I, but in Study II only 
the tumor with worrisome histology was included. From Study II a patient was excluded 
who had MEN2 with adrenal tumor, which was in Study I, because following further 
consideration it suited better to the diagnosis hyperplasia of adrenal medulla than PHEO. 
The origin of four large tumors in the vicinity of the adrenals was reexamined from the 
operation protocols, and the organ adrenal based on pathological reports was changed to 
retroperitoneum in three of these four cases. PGLs constituted 16% of tumors. Of the 146 
patients (Study II), 23 had a PGL and 123 a PHEO. 
 
Study III included a subset of 16 patients, who were also included in Studies I and II. Eight 
patients had a metastatic disease and eight a nonmetastatic disease, eight had a PGL and 
eight a PHEO. In the metastatic group (Studies I–III), metastases were confirmed either 
histologically or radiologically by MIBG or SSTR scintigraphy. 
 
Study IV included thyroid PGLs from a population-based European-American-Head-and-
Neck-Paraganglioma-Registry, which is located in Freiburg, Germany. Eight patients in the 
registry were initially diagnosed as having a thyroid PGL but after reevaluation of the 
diagnoses morphologically and by IHC, five thyroid PGL diagnoses were confirmed. For 
all eight patients, registered demographic information was reevaluated and genetic testing 









Table 8. Tumor material in the original publications. 
 
Study I II III IV 
Patients 147 146 16 5 
Pheochromocytomas 131 127 8 0 
Paragangliomas 22 24 8 5 
Tumors associated 



















Figure 6. Patient cohorts in Studies II–IV. Study II: the metastatic tumors (n=14) are 
depicted in purple color and the nonmetastatic ones (n=137) in light green color. Study III: 
the metastatic tumors (n=8) are shown in dark orange and the nonmetastatic tumors ones 
(n=8) in light orange. Thyroid PGLs in Study IV (blue color) are a separate group. The areas 
are not in proportion to the size of the cohorts. 
 
 
 Tissue microarray blocks 
For construction of tissue microarray (TMA) blocks (Studies I and II), H&E slides were 
reevaluated and representative areas from the primary tumors chosen. The chosen areas 
were located near the border of the tumors to ensure good fixation in the tumor cells. Only 
vital areas were chosen. Three 1 mm tumor punctures were drawn from analogous tissue 













blocks and inserted into a recipient paraffin block with a semiautomatic tissue microarrayer 
(Beecher Instruments, Silver Spring, MD, MTABooster® Version 1.01 for Beecher Manual 
Arrayer, Alphelys). From each TMA block, one slide was cut to obtain three spots per tissue 
sample for immunohistochemical analysis. Proper sampling was controlled histologically 
by H&E and chromogranin A stainings. 
 
 Immunohistochemistry and scoring 
The TMA blocks were cut into 4 μm thick sections and processed through deparaffinization 
in xylene followed by rehydration with graded alcohol series. The TMA slides were 
pretreated in a pretreatment module (LabVision UK Ltd, Suffolk, UK) with Tris-HCl buffer 
pH 8.5 for 20 min at 98°C (HuR19A12, HuR3A2, COX-2, MIB1, chromogranin A), with 
Tris-EDTA pH 9 for 25 min at 98°C (synaptophysin, cytokeratin-pan, TTF1, p53), with 
citrate buffer pH 6.0 for 25 min at 98°C (SSTR1, SSTR3-5) or no pretreatment done (S-
100, calcitonin). SSTR2 antibody pretreatment was done with Cell Conditioning Solution 
(CC1) for 30 min in a Benchmark XT (Roche, Tucson, AZ, USA). Details of antibodies, 
dilutions, and scoring are shown in Table 9. A peroxidase-conjugated polymer kit Envision 
(Agilent, Santa Clara, CA, USA) was used to detect antigens in an Autostainer 480 
(LabVision Thermo Scientific UK Ltd, Cheshire, UK), except for SSTR2 which was 
detected with an Optiview DAB kit in a Benchmark XT (Roche, Tucson, AZ, USA). 
Counterstaining was done with Mayer’s Hematoxylin (Lillie’s Modification) (Agilent, 
Santa Clara, CA, USA) and mounting with Eukitt® mounting medium (Sigma-Aldrich, St. 
Louis, MO, USA). Immunohistochemical stainings with SDHB antibody 21A11 (ABCAM, 
Cambridge, MA, USA) and SDHA antibody 5A11 (ABCAM) were done as previously 
described (Miettinen et al. 2014). Scoring was performed independently by two pathologists 
(J.H. and H.L. in Studies I and II, M.M. and H.L SDHB and SDHA IHC and J.A. and H.L. 
in Study IV) without any knowledge of the clinical data. Cases of disagreement required a 
consensus score. Colon adenocarcinoma was used as a positive control for HuR19F12, 
HuR3A2, and COX-2 stainings and pancreatic islet cells and small intestine neuroendocrine 
cells for SSTR1–5. Tissues not expressing these proteins like those from the kidney and 

















Table 9.  
Details of the antibodies used and scoring. 
 
Antibody Study Clone Company Dilution Scoring used 
Ki-67 I, II, III, IV MIB1/M7240 monoclonal Agilent 1:100 
Percentage of positive tumor cells 
HuR19F12 I HuR19F12 monoclonal 
Gift from Dr 
Furneaux, UCHC, 
Farmington, CT, USA 
1:30 000 
Intensity of staining 0=0, 1=weak, 2=moderate, 
3=strong 
(both cytoplasmic and nuclear staining scored) 
(Leijon et al. 2016) 
HuR3A2 I HuR3A2 monoclonal 
Santa Cruz 
Biotechnology 1:1500 
Same as above 
COX-2 I COX-2 monoclonal Cayman Chemical 1:100 
Same as above, only cytoplasmic staining 
SSTR1 II sstr1 monoclonal AbD Serotec 1:500 
0=0 
1<10%, weak cytoplasmic positivity 
2≥10% weak cytoplasmic positivity 
3=moderate cytoplasmic positivity 
4=strong cytoplasmic positivity* 
(Modified from Elston et al. 2015) 
SSTR2 II UMB-1 monoclonal Abcam 1:300 
 0=0 
1<10%, not totally circumferential membrane 
positivity 
2≥10% not totally circumferential membrane 
positivity 
3=strong circumferential membrane positivity in 
10–94% of tumor cells 
4=strong circumferential positivity in ≥95% of 
tumor cells** 
(Modified from Elston et al. 2015) 
SSTR3 II UMB-5 monoclonal Abcam 1:7000 





If <10% of tumor cells positive, downgraded by 
one grade *** 
SSTR4 II sstr4 monoclonal AbD Serotec 1:500 
Same as SSTR1 
SSTR5 II sstr5 monoclonal Bio-RAD 1:1000 
0=0 
1<10%, weak cytoplasmic positivity 
2≥10% weak cytoplasmic positivity 
3=moderate cytoplasmic or some membrane 
positivity 
4=strong cytoplasmic positivity or membrane 
positivity* 
(Modified from Elston et al. 2015) 
Chromogranin 
A I, II, III, IV 
Rabbit 
polyclonal Agilent 1:2000 
Positive/negative 






(Miettinen et al. 2014) 
























* For statistics, the scores for SSTR1, 4, and 5 were grouped into three groups: negative (score 0 and 1), intermediate positive (score 2 
and 3), and strong (score 4). 
** For statistics, the SSTR2 scores were grouped into three groups: negative (score 0 and 1), intermediate positive (score 2), and strongly 
positive (score 3 and 4). 
*** For statistics, the SSTR3 scores were grouped into three groups: negative (score 0), intermediate positive (score 1), and strong (score 
2 and 3). 
 
 
  Mass spectrometric N-glycan profiling 
From representative tumor areas of formalin-fixed, paraffin-embedded tissue blocks were 
punched samples with a volume of at least 1 mm3 for mass spectrometric analysis. The 
samples were deparaffinized with xylene and with an ethanol–water series according to 
standard procedures. By peptide N-glycosidase F digestion, asparagine-linked glycans were 
detached from tissue glycoproteins and purified by a series of microscale solid-phase 
extraction steps as previously described (Kaprio et al. 2015). Acidic N-glycans were 
analyzed in negative ion linear mode as [M-H]− ions and neutral N-glycans in positive ion 
reflector mode as [M+Na]+ ions. Based on their relative signal intensities, the relative molar 
quantity of neutral and acidic glycan components was assigned. The mass spectrometric raw 
data were processed into the current glycan profiles as in previously described protocols. 
The glycan profiles were normalized to 100% to allow comparison between samples 
(Satomaa et al. 2009a, b, Kaprio et al. 2015). 
 
 
  Genetic analysis 
 
The patients in Study IV were tested for germ-line mutations of genes which have been 
associated with HNPGLs: SDHA, SDHAF2, SDHB, SDHC, SDHD, VHL, RET, MAX, and 
TMEM127 (Neumann et al. 2004, Schiavi et al. 2005, Burnichon et al. 2010). The mutations 





























13–16 were studied. DNA for genetic studies was obtained from EDTA-anticoagulated 
whole blood. Bidirectional Sanger sequencing of the coding regions and splice sites of all 
genes was done. To find a deletion or duplication of the above-mentioned genes, multiplex 
ligation-dependent probe amplification analyses for VHL, SDHB, SDHC, SDHD, SDHAF2, 
MAX, and SDHA and semiquantitative multiplex polymerase chain reaction (PCR) for 
TMEM127 were done. To clarify the extent of large deletions, break points were detected 
through quantitative real-time PCR gene-dosage determination and characterized by long-
range PCR and nucleotide sequencing. The DNA variants were evaluated with three in silico 
analyses (SIFT, MutationTaster, PolyPhen). If at least two of the three software packages 




 Statistical analysis 
 
In Studies I and II, the chi-square test or Fisher’s exact test when applicable were used for 
comparisons of immunohistochemical, histological, and clinicopathological variables. A 
P value less than 0.05 was regarded as statistically significant. Tumor size was compared 
between nonmetastasized and metastasized tumors using the Mann–Whitney test. Statistical 
analyses were performed with SPSS version 20.0 software (IBM SPSS Statistics, SPSS Inc., 
Chicago, IL, USA). 
 
In Study III, m/z variables with all values equal to zero or with the total sum of the m/z 
values less than 1.5% were removed before importing the data into the software. Principal 
component analysis (PCA) was done using default parameters (analysis based on case-wise 
missing data deletion and correlations). To compare differences in the glycan structures 
between the nonmetastasized and metastasized tumors, the Mann–Whitney test was used. 
When a statistically significant difference was found via the Mann–Whitney test, the mean 
relative amounts of glycan structures, the standard errors of the mean, and the fold 
difference of the means between the groups were calculated. Error propagation served to 
assess standard error of the fold difference. Every test was two-sided. For multiplicity 
testing adjustment, the Benjamini–Hochberg procedure with the false positivity rate of 0.15 
was used. Statistical analyses were performed with Statistica version 12.6 (StatSoft, Tulsa, 
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  Clinical, histopathological data, and proliferation (Studies I 
and II) 
 
In the cohort of 146 patients, 83 were female and 63 were male, and 13 patients (8.9%) had 
a metastatic disease. Of the patients with a metastatic disease, 10 were male and 3 were 
female. The metastasized tumors included nine PGLs and five PHEOs. Of the PHEOs 4% 
were metastatic and 38% of the PGLs. The mean tumor size in the metastatic group was 
112 mm, and it was 65 mm in the nonmetastatic group. The metastatic tumors had a higher 
proliferation index and more frequently tumor necrosis (Table 10). 
 
Of the patients, 8% were known to have MEN2, 3% NF1, 5% von Hippel–Lindau syndrome, 
and based on our results, of those with SDHB IHC, 10% had SDHx mutation. Eight patients 
were known to have multifocal disease. All these patients were syndromic. Three had 
MEN2, three known SDHB mutation, and two VHL. 
 
Table 10. Differences in proliferation (MIB1), size, and frequency of tumor necrosis 







Mean MIB1 1.6% 5.6% P<0.0001* 
Range of MIB1 0–9% 1–12%  
Mean size 65 mm 112 mm P<0.0001** 
Range of size 6–120 mm 45–192 mm  
Tumor necrosis 14/137 5/14 P=0.023* 
 









 Immunohistochemistry results 
 Human antigen R protein (Study I) 
 
Metastatic PHEOs and PGLs had significantly more cytoplasmic HuR protein staining than 
nonmetastatic tumors with both HuR antibodies used. Also COX-2 staining was increased 
in metastatic tumors. Cytoplasmic HuR staining was associated with COX-2 positivity 
(P<0.0001, Fisher’s exact test) and high MIB1 values (P<0.0001, Fisher’s exact test). The 
tumors with histologically worrisome features expressed significantly more cytoplasmic 
HuR19F12 protein than tumors without worrisome histology. The tumors with vascular 
invasion had also more cytoplasmic HuR19F12. The results are summarized in Table 11. 
Figure 7 visualizes the stronger cytoplasmic staining in metastasized PHEOs and PGLs with 
HuR19F12 antibody in comparison with nonmetastasized tumors. 
 
 
Table 11. Comparison of the immunohistochemistry (IHC) findings between metastatic and 




Antibody P value Result 
MIB1 <0.0001* Higher proliferation in metastatic than in 
nonmetastatic tumors 
HuR19F12 cytoplasmic  <0.0001* Stronger IHC expression in metastatic tumors than 
in nonmetastatic tumors 
HuR19F12 cytoplasmic 0.021* More abundant IHC expression in tumors with 
vascular invasion 
HuR19F12 cytoplasmic 0.004* Stronger IHC expression in nonmetastatic tumors 
with one or more histologically worrisome feature 
versus tumors without such features 
HuR3A2 cytoplasmic <0.0001* Stronger IHC expression in metastatic tumors than 
in nonmetastatic tumors  
COX-2 <0.0001* Stronger IHC expression in metastatic tumors than 
in nonmetastatic tumors  
 













Figure 7. Comparison of immunohistochemical cytoplasmic HuR19F12 staining score (0–
3) between nonmetastatic (n=139) and metastatic (n=15) pheochromocytomas (PHEOs) and 
paragangliomas (PGLs). The metastatic tumors express significantly more abundantly 










  Somatostatin receptors in pheochromocytomas and paragangliomas 
(Study II) 
 
151 primary PHEOs and PGLs were examined immunohistochemically with somatostatin 
receptor antibodies (SSTR1–5). The two most abundantly expressed somatostatin receptors 
were SSTR2 and 3. Table 12 shows SSTR1–5 expression in 151 PHEOs and PGLs 
including 14 metastatic tumors. SSTR1 expression was more abundant in PGLs than PHEOs 
(P=0.028, Fisher’s exact test). Of PHEOs, 4.8% (6/125) showed weak SSTR4 positivity in 
>10% of tumor cells, while all PGLs were negative. With SSTR2, 3, and 5 antibodies no 





















Cytoplasmic HuR19F12 score in 153 PHEOs and PGLs




Table 12. Immunohistochemical somatostatin receptor (SSTR1–5) expression in 151 




























































































The scoring of immunohistochemistry has been described in Table 9. 
 
 
 Somatostatin receptor expression in metastatic tumors 
 
Of the metastasized tumors, 10/14 were strongly SSTR2 positive (9 PGLs, 1 PHEO); thus 
the metastatic PGLs were expressing significantly more SSTR2 than the PHEOs (P=0.005, 
Fisher’s exact test). Three metastatic PHEOs were completely SSTR2 negative (Table 13). 
 
Metastatic tumors showed less SSTR3 positivity than nonmetastatic tumors (P=0.005). 
Among the metastatic tumors, 42.9% (6/14) were completely SSTR3 negative and 57.1% 
(8/14) intermediate or strongly positive, while of the nonmetastasized tumors 19.7% 
(27/137) showed no SSTR3 positivity and 80.3% (110/137) were intermediate or strongly 
positive. Also, tumors with high MIB1 value expressed less SSTR3. For other SSTR 
subtypes no differences between metastatic and nonmetastatic tumors emerged. However, 













Table 13. Immunohistochemistry (IHC) staining results in 13 patients with metastatic 




























Abbreviations and color codes: 
Somatostatin receptor (SSTR): S = strongly positive (red color); I = intermediate positive 
(orange color); N = negative (light yellow); NA = not available; SDHB = succinate 

































I S S N N + 
M 53 Retroperitoneum N S I N I − 
F 46 Neck N S N N N − 






N S N N N − 
M 31 Retroperitoneum N S S N N − 
M 48 Retroperitoneum I S N N N − 
M 39 Retroperitoneum I S S N N − 
M 51 Adrenal N S I N N + 
M 45 Adrenal I N N N N + 
M 69 Adrenal N N S N N + 
M 19 Adrenal N I I N N + 




 SDHB and SDHA immunohistochemistry expression (Studies II and 
III) 
 
Sixteen SDHB IHC negative primary tumors were found. They were all PGLs: 12 
retroperitoneal, three thoracic, and one neck. Of the 146 patients, 15 (10.3%) had SDHB-
negative tumors, and of the SDHB-deficient patients, 40% (6/15) had a metastatic disease. 
The patients who had SDHB-negative tumors were younger at diagnosis than the SDHB-
positive patients. The median age of the SDHB-negative patients was 36 years (range 22– 
53 years) and that of the SDHB-positive patients was 53 years (range 17–87 years). SDHA-
negative tumors were not found in this cohort. The SDHB status was not associated with 
IHC expression of SSTR1–5. 
 
  Glycomics (Study III) 
 
N-glycans were analyzed in eight PHEOs and eight PGLs using matrix-assisted laser 
desorption/ionization time of flight mass spectrometric profiling. The N-glycan profiles 
were compared between metastasized (n=8) and nonmetastasized (n=8) tumors and between 
PHEOs (n=8) and PGLs (n=8). Both among acidic N-glycans and neutral N-glycans, we 
found more abundant fucosylation and complex fucosylation in metastatic PGLs and 
PHEOs than in nonmetastatic tumors. Among neutral N-glycans, also the hybrid-type N-
glycans was more abundant in the metastatic group. The differences were statistically 
significant for individual tests, but when adjusted for multiplicity testing, they were above 
the false positive critical rate. Results for individual tests are in Table 14. 
 
 
Table 14. Differences in neutral (A) and acidic (B) N-glycosylation between 
nonmetastasized and metastasized pheochromocytomas and paragangliomas. 
 
 






Ratio of mean ranks, 
metastasized/nonmetastasized 
Ratio of means, 
metastasized/nonmetastasized 
P value* 
Fucosylation 1.89 1.31 0.028 
Complex 
fucosylation 1.75 1.90 0.049 












Ratio of mean ranks, 
metastasized/nonmetastasized 
Ratio of means, 
metastasized/nonmetastasized 
P value* 
Fucosylation 1.89 1.12 0.028 
Complex 





  Neutral and acidic asparagine-linked glycan profiles 
 
Neutral asparagine-linked glycan profiles 
High-mannose type N-glycans were the five most abundant glycan signals, with 
compositions H5N2, H6N2, H7N2, H8N2, and H9N2. In metastatic tumors, four groups of 
neutral N-glycan signals were more abundant than in nonmetastatic tumors. Among these 
were 1) multifucosylated glycans, such as H4N3F2, H5N4F3, and H5N5F3; 2) a complex-
type N-glycan signal that has been shown to indicate cancer-associated terminal N-
acetylglucosamine; 3) hybrid-type N-glycans, such as H6N3F1; and also 4) fucosylated N-
glycans such as H3N2F1, identified as paucimannose type based on their monosaccharide 
composition, were more abundant in metastatic tumors, whereas non-fucosylated 
paucimannose glycans such as H3N2 appeared more in nonmetastatic tumors. 
 
Acidic asparagine-linked glycan profiles 
Regarding acidic asparagine-linked glycan profiles, glycan signals composed of no or only 
one deoxyhexose residue (fucose), such as S1H5N4, S1H5N4F1, S2H5N4, and S2H5N4F1, 
occurred more in nonmetastasized tumors. In metastatic tumors, three groups of acidic N-
glycans were more abundant: 1) multifucosylated N-glycans, such as S1H5N4F2 and 
S1H6N5F3; 2) acid ester-modified (sulfated or phosphorylated) glycans, such as 
H4N3F1P1, H3N4F1P1, and H4N5F2P1; and 3) hybrid-type/monoantennary N-glycans, 
















  Principal component analysis 
 
PCA of the glycan profiling data could separate both the metastatic and nonmetastatic 
tumors and PGLs and PHEOs in distinct areas (visualized in Figure 8). The number in PCA 






Table 15. Characteristics of 16 patients with pheochromocytoma (PHEO) or paraganglioma 





















1 M 19 PHEO M NF1 + 30 
2 M 69 PHEO M ND + 0 
3 M 45 PHEO M ND + 19 





5 M 39 PGL M SDHB − 15 
6 M 48 PGL M ND − 8 
7 M 31 PGL M SDHB − 21 
8 F 57 PGL M No * + 10 
9 F 59 PHEO  No (RET) + 7 
10 F 57 PHEO  ND + 10 
11 M 50 PHEO  No (RET) + 8 
12 M 43 PHEO  No (RET) + 9 
13 F 34 PGL  SDHB − 11 
14 M 77 PGL  ND + 3 
15 M 48 PGL  SDHB − 16 
16 M 23 PGL  ND − 16 
*(MAX, VHL, NF1, REPRKAR1A, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127) 
Abbreviations: ND not determined SDHB, succinate dehydrogenase subunit B, sufficient +, 










Figure 8. Differences in glycosylation of metastatic and nonmetastatic 
pheochromocytomas (PHEO) and paragangliomas (PGL) visualized in principal 
component analysis (PCA). Visualization of neutral (A) and combined neutral and acidic 
(B) N-glycan structures as PCA results on factor planes 1 and 2. The percentages indicate 
the amount of variance captured by each of the factors (1 or 2). Dotted lines illustrate the 
clustering of PHEOs and PGLs in neutral glycan PCA (A) and metastasized and 




PHEO; light green, nonmetastasized PHEO; dark red, metastasized PGL; dark green, 
nonmetastasized PGL. Numbers refer to the patient numbering in Table 15. Two SDHB-
negative PGL tumors (5 and 13, marked with striped background) clustered with the 
opposite sample group (Leijon et al.2017) 
Reproduced with the permission of Oxford University Press. 
 
 Thyroid paragangliomas (Study IV) 
  Clinical characteristics 
 
The prevalence of thyroid paraganglia was 0.5% (5/944) of all HNPGLs in the European-
American-HNPGL-Registry. The clinical findings of five thyroid PGL patients are in 
Table 16. The age at diagnosis varied between 27 and 71 years, the median age being 
40.6 years. Family history of SDHB mutation was known only in one patient (case 1). All 
patients underwent either total thyroidectomy or hemithyroidectomy. After a median 
follow-up of 5 years, no one had developed metastasis, but case 4, a 37-year-old female, 
had a recurrent PGL after the first operation. 
 





















NA PGL After 1st operation SDHB 
2 M 32 Node in the 
neck 
Adenoma PGL After 1st operation SDHB 




After 3 years SDHA 








After 12 years SDHA 
5 F 71 Dysphagia Follicular 
neoplasia 
PGL After 1st operation Not in nine 
tested 
genes 








  Histology and immunohistochemistry in thyroid paragangliomas 
 
 
The histological and immunohistological findings were quite similar in all five thyroid 
PGLs. Morphology included fibrous septa and dense vascularization. The chief cells with 
clear or basophilic abundant cytoplasm formed nests (the classic Zellballen) and sheets. 
Some nuclear variation was seen and the mitotic rate was low. S-100 positive sustentacular 
cells were found as well. 
 
In IHC stainings, chief cells were positive for chromogranin A and synaptophysin. Negative 




 Molecular genetic results 
 
Nine known predisposition genes for PGLs were analyzed: SDHA, SDHAF2, SDHB, SDHC, 
SDHD, VHL, RET, MAX, and TMEM127. Four out of five patients had germ-line DNA 
variants in the SDHx genes: two in the SDHB and two in the SDHA gene. A 27-year-old 
man had germ-line SDHB mutation c.664G>Ap.Arg177His. Eight of his 10 relatives were 
also mutation carriers, six having PGL or PHEO. Another 32-year-old male was found to 
have a complex rearrangement of the SDHB gene, consisting of a partial deletion of intron 2 
and exon 3, and an Alu insertion. There were no additional PGLs in his family history. Two 
patients had germ-line DNA variants of the SDHA gene, which were probably mutations 
rather than polymorphisms according to silico analyses. No family history of PGLs could 
be found in these patients. All four patients with SDHx mutations were under 40 years of 












PHEOs and PGLs constitute a rare and heterogeneous tumor group, with genetic, molecular, 
and histological variation and with differences in prognosis. Therefore, studies with these 
tumors are challenging to perform. Many studies have tried to find clinical, histological, or 
immunohistochemical biomarkers that are associated with aggressive behavior of PHEOs 
and PGLs. Although the knowledge of this tumor group has increased a lot during recent 
years, we still have no unequivocal widely accepted and validated means to predict the 
outcome of an individual PHEO or PGL. 
 
Genetic factors and prognosis in pheochromocytomas and paragangliomas 
The traditional 10% rule claiming that 10% of PHEOs are malignant, 10% bilateral, 10% 
extra-adrenal, and 10% hereditary does not apply anymore, as about 30–40% of tumors are 
known to have hereditary background (Pillai et al. 2016, Crona et al. 2017, Tischler et al. 
2017). Our cohort of 153 consecutive PHEOs and PGLs with a long follow-up time and 
clinical data is comprehensive regarding the rarity of these tumors. PGLs constitute 16% of 
this cohort. Less than 10% of tumors were metastatic (4% of PHEOs and 38% of PGLs), 
which is less than reported. It is possible that some patients still develop metastases, as the 
latest tumors were operated in 2009, and late metastases occur. Some tumors with metastatic 
potential may have been diagnosed and operated radically before metastases occurred. The 
hereditary background in our cohort was not fully studied. The oldest tumors in this cohort 
were treated before genetic testing was common practice. However, 8% of the patients were 
known to have MEN2, 3% NF1, 5% von Hippel–Lindau syndrome, and based on our results 
of SDHB IHC, 10% were known to have SDHx mutation. Eight patients were known to 
have multifocal disease. All these patients were syndromic. Three had MEN2, three had 
known SDHB mutation, and two had VHL. Of SDHB mutation carriers’ tumors, which 
mostly are PGLs, about 30% metastasize, and SDHB mutation is nowadays the strongest 
predictive factor of aggressive behavior of these tumors. In this Finnish cohort, 40% of the 
patients with immunohistochemically SDHB-negative tumors had metastatic disease. IHC 
is known to be a sensitive and specific method to identify SDHB mutation. No SDHA 
mutation was found. Knowledge of different genetic backgrounds and prognosis has 
increased, but it is by no means complete and probably new genes will be found. Individual 
targeted genetic testing is recommended for every PGL and PHEO patient. Identification of 
an inherited pathogenic mutation has clinical impact. It can lead to early diagnosis of 
multiple tumors and metastases in the patient and investigations of the relatives at risk. The 
genetic background has an impact on tumor pathogenesis. Thus, probably the same 
prognostic and predictive markers may not be valid for all PHEOs and PGLs. 
 
With understanding the role of SDHx mutations, prediction of the metastatic potential of 
PHEOs and PGLs has become slightly more accurate; however, new prognostic markers are 
still needed. Location of the primary tumor plays a role as PGLs metastasize more often 




comprising 290 tumors, the location of the primary tumor was a stronger predictor of 
metastases than the size in multivariate analysis, but metastatic PHEOs and PGLs were also 
larger than nonmetastatic ones. The mean size of the primary tumors of the metastatic 
neoplasms was 8.2 cm and that of the nonmetastatic ones 4.9 cm (Ayala-Ramirez et al. 
2011). The size was important also in our study, in which the tumors were larger than in the 
study of Ayala-Ramirez. However, among the few metastasized cases we had one very large 
19.5 cm PHEO which increased the mean metastasized tumor size. The smallest primary 
tumor associated with metastatic disease was 4.5 cm in diameter. 
 
 
Basic histopathology and cell proliferation in diagnostic and prognostic evaluation of 
pheochromocytomas and paragangliomas 
A high proliferation rate of tumor cells analyzed by counting mitosis or MIB1/Ki-67 has 
been associated with aggressive potential (August et al. 2004, de Wailly et al. 2012). In our 
cohort, metastasized tumors had higher MIB1 values. Despite the difference in the 
proliferation index between metastasized and nonmetastasized PHEOs and PGLs, over half 
of metastasized tumors had an MIB1 value below 5%. The highest MIB1 value in 
nonmetastasized tumors was 9%. Thus, high proliferation rate is only a single risk factor for 
metastatic disease and is not sufficient to predict the metastatic potential alone. 
 
Histological parameters such as necrosis, invasion, and mitotic count have previously been 
shown to be associated with metastatic disease (Salmenkivi et al. 2003a). In our cohort, 
necrosis occurred significantly more often in the metastatic group. Necrosis is an important 
factor reflecting the aggressive potential of tumors, but alone it gives limited information of 
prognosis. Both capsular and vascular invasion were more frequent in our cohort in 
metastasized tumors, but the difference was not statistically significant. These parameters 
are included in the most commonly used score systems – the PASS and GAPP scores 
(Thompson 2002, Kimura et al. 2014a). Traditional histology does not give an answer as to 
how a single tumor will behave, but risk stratification of a PHEO or PGL is recommended 
(Tischler et al. 2017). 
 
No consensus has been reached regarding an adequate scoring system, but it should 
probably combine different factors as proposed in the PASS and GAPP scores (Thompson 
2002, Kimura et al. 2014a). The proposed scoring systems have many common factors, 
which have been shown to be associated with metastatic potential. The factors to be scored 
should have clear criteria to avoid intra- and interobserver variation. To keep the scoring 
practical in clinical practice, it should not be too complicated and should include only factors 
most strongly associated with the metastatic potential of PHEOs and PGLs. In our results, 
both necrosis and MIB1 were significantly associated with metastatic disease. Both are 
factors which have been shown to be associated with the aggressive potential of tumors also 
in other neoplasms like adrenal cortical tumors (Pennanen et al. 2015) and 
leiomyosarcomas. Because necrosis and proliferation as single parameters are associated 
with metastatic potential, they probably are important histological hints to the 
aggressiveness of the tumor. A novel scoring system of adrenal cortical tumors, the Helsinki 
score, estimates the aggressive potential of the tumor by the amount of proliferation and the 
existence of necrosis (Pennanen et al. 2015). Maybe a score including necrosis, proliferation 







PGLs can occur also in very rare locations. As a separate cohort, we studied thyroid PGLs. 
Because of the rarity of this tumor, the diagnosis can be challenging and IHC is needed to 
confirm the diagnosis. Initially eight cases with a diagnosis of thyroid PGL were included 
in the European-American-HNPGL-Registry. After morphological and 
immunohistochemical reevaluation, the diagnosis of thyroid PGL could be confirmed only 
in five cases. The number of patients was very low, but according to our findings thyroid 
PGLs are strongly associated with SDHx mutations. Two patients had germ-line SDHB 
mutations and two had SDHA mutations, but in one patient none of the tested mutations was 
found. Thyroid PGLs seem to have a rather indolent clinical behavior according to our 
results. During the 5 years of follow-up, no metastases evolved. 
 
Human antigen R’s role as a biomarker for pheochromocytomas and paragangliomas 
HuR protein is an example of a biomarker that can serve as a prognostic marker. In our 
cohort the majority, but not all, metastatic tumors showed increased intracytoplasmic HuR 
positivity, while the majority of nonmetastatic tumors were negative or only weakly 
positive. This was a new observation. Differences in the PHEO- and PGL-associated genes 
and mutations, known to affect pathogenesis, could explain the differences in HuR 
expression in metastatic tumors. HuR is involved in very complex posttranslational 
regulation and it has many different targets. Some of its functions and targets are probably 
still unknown as are its interactions with other factors. In many malignancies, 
intracytoplasmic HuR expression has been shown to be increased, and in most works 
increased HuR expression has been shown to be associated with higher tumor stage and 
worse prognosis, but even contradictory results have been published. In a study by 
Costantino et al. (2009), pancreatic cancer patients with high cytoplasmic HuR had lower 
mortality probably because HuR enhances the efficacy of gemcitabine. In breast cancer, 
high HuR expression has also been associated with a better prognosis (Yuan et al. 2010). 
Among malignancies with increased HuR expression are epithelial malignancies like oral 
squamous cell carcinoma (Cha et al. 2011), colorectal adenocarcinoma (Denkert et al. 
2006), and mucinous-type ovarian carcinoma (Erkinheimo et al. 2005). Also, a 
neuroendocrine skin tumor, Merkel cell carcinoma (Koljonen et al. 2008), and neural tumors 
medulloblastoma and glioblastoma have increased HuR expression (Nabors et al. 2001). In 
neural crest derived neuroendocrine PHEOs and PGLs, more abundant cytoplasmic HuR 
expression is associated with metastatic potential in our study. Because of heterogeneity of 
malignancies associated with increased HuR expression, HuR seems to be a shared and 
common posttranslational factor in malignant transformation. Drugs which could inhibit 
HuR would be tempting, but one should know thoroughly the targets of HuR, the end results 
of its interactions, and also its impact on physiological processes. 
 
N-glycans in pheochromocytomas and paragangliomas 
Both the effect of HuR and changes in glycan structures are posttranslational events which 
can participate in malignant transformation. Cancer-associated asparagine-linked glycan 
(N-glycan) structures are involved in tumor progression and growth. We analyzed N-glycan 
profiles of eight PHEOs and eight PGLs and found differences between metastatic and 
nonmetastatic tumors, which was new knowledge. In metastasized PHEOs and PGLs, 
complex-type N-glycan signals of cancer-associated terminal N-acetylglucosamine, were 
more abundant than in nonmetastasized tumors. Interestingly this N-glycan structure has 
been shown to be increased in other malignancies like breast, lung, kidney, ovary (Satomaa 




the pathogenesis of many tumors. In metastasized PHEOs and PGLs, fucosylation and 
complex fucosylation were more common than in respective nonmetastasized tumors, 
which differs from rectal tumors in which complex fucosylation is more common in benign 
adenomas than in cancers. PCA could separate metastasized and nonmetastasized tumors, 
but also PHEOs and PGLs, which strengthens the idea that PHEOs and PGLs have 
differences in their biology and behavior. N-glycans can be measured in serum and used as 
antigens in IHC. Identifying N-glycans, which are associated with aggressive behavior of 
PHEOs and PGLs, can in the future give some diagnostic and prognostic biomarkers for 
these tumors. 
 
Somatostatin receptors in pheochromocytomas and paragangliomas 
Only limited treatment options are available for metastatic PHEOs and PGLs. With 
increasing knowledge of the genetic background and pathogenesis associated with different 
mutations, also new targeted therapies can be developed, which hopefully will open new 
possibilities to treat metastatic disease (Roman-Gonzalez and Jimenez 2017). SSTR analogs 
can be used in imaging and in PRRT treatment of these tumors. According to our IHC 
results, PHEOs and PGLs have variable individual SSTR profiles. With the development of 
new SSTR analogs with affinity to several SSTR receptors and increased experience and 
validation of new monoclonal SSTR antibodies, it is possible that IHC can assist in the 
selection of an adequate SSTR analog for imaging and treatment targeted to a suitable 
subgroup of these tumors. According to our results, metastatic PHEOs and PGLs had 
different SSTR2 expression, which is an additional difference between PHEOs and PGLs. 
The differences in tumors´ SSTR expression could influence treatment and imaging 
practices. Metastatic and actively proliferating tumors expressed less SSTR3 than 
nonmetastatic tumors. The loss of SSTR3 expression may give a hint of a tumor’s aggressive 
behavior, but larger studies combining clinical information and long follow-up would be 
needed to investigate this. 
 
 
Strengths and limitations of our study 
A large consecutive tumor cohort with clinical data attached to it is a strength. Also, a new 
technical approach like glycomics is beneficial to this reseach. A long follow-up time as 
included in our study is also obligatory to find out the true nature of the tumors. A limitation 
is the relatively low number of metastatic tumors due to the rarity of these neoplasias. This 
does not allow us to intepret our results too strongly. Nationwide biobank research would 
be beneficial to increase the number of both metastatic and nonmetastatic cases. Also, 
international collaboration such as in the thyroid PGL work would be of interest and would 
make it possible to collect more representative cases of rare lesions. Studies I and II are 
based on TMA material, which has some limitations. Some tumors express proteins in a 
heterogeneous fashion. TMA spots represent only a minority of the tumor area, which can 
cause some bias in the results. On the other hand, a traditional whole slide of the tumor 
represents only a small part of the neoplasm too. Many methodological and technical 
problems and errors are possible in IHC. There may be variations in fixation time among 
the tumors, which can impact the staining results. Also, the IHC staining process has many 
steps, which all should be done in an optimal fashion to get reliable results. Estimating IHC 
staining results is to some extent subjective, and intra- and interobserver variation occur. 
Most biological processes are a continuum and choosing the cutoff points of IHC scores is 
somewhat artificial too. With IHC we can demonstrate the presence of a protein in tumor 




finding. Studies combining broad clinical, long-term follow-up information and IHC results 
would be beneficial. For example, studies where somatostatin analog based imaging results, 




As the heterogeneity in genetic background and pathogenesis of PHEOs and PGLs continue 
to become more evident, more diagnostic and treatment options will become available. 
Targeted therapies will become available as well. Adequate biobank samples including 
collections of a large number of rare disease cases will play a key role in the future, and 
patients with rare tumors like PHEOs and PGLs should be recruited for research. As 
molecular testing is becoming essential, liquid biopsies and cell-free tumor DNA can 






The main conclusion is that expression of HuR, SSTR subtype profile, and N-glycomic 
profile may be used as potential biomarkers in PHEOs and PGLs. However, prediction of 
the behavior of a single PHEO or PGL is still uncertain. 
 
The specific conclusions of this thesis are: 
 
1. The majority of metastatic PHEOs and PGLs express moderately to strongly 
intracytoplasmic HuR protein, while the majority of nonmetastatic tumors are negative or 
only weakly positive. Thus strong intracytoplasmic HuR expression can point to metastatic 
potential in these tumors. 
 
 
2. The SSTR1–5 profile of PHEOs and PGLs is individual and variable with the strongest 
expression of SSTR2 and SSTR3. Metastatic PGLs were all SSTR2 positive, while most 
metastatic PHEOs were negative. SSTR3 expression was lower in metastatic and actively 
proliferating tumors. No association with SSTR subtypes and SDHB status was found. 
 
 
3. Fucosylation and complex fucosylation are more common in metastatic than 
nonmetastatic PHEOs and PGLs. Four neutral N-glycan groups and three acidic N-glycan 
groups are associated with metastatic disease. 
 
 
4. Thyroid PGLs are rare tumors which constitute about 0.5% of HNPGLs. They have a 
strong association with SDHx mutations. Thyroid PGLs have a similar histology and IHC 
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